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Traumatic brain injury is a significant cause of death and disability and accounts for 16% 
of injury-related emergency department visits in the United States. Current guidelines for 
management of traumatic brain injury are focused on identifying and preventing 
secondary brain injury using multimodal invasive monitoring techniques, including 
cerebral oxygenation monitoring. However, these approaches have risks and there is 
currently no clinical consensus that use of invasive monitoring improves patient 
functional outcome. We will evaluate whether noninvasive monitoring of cerebral 
oxygenation with near infrared spectroscopy can reduce the median duration of 
brain tissue hypoxia in patients with severe traumatic brain injury. Specifically, we 
will determine whether this method has benefit in combination with current guidelines, 
versus management based on current guidelines alone. This study will provide evidence 
that noninvasive cerebral oxygenation monitoring is a physiologic parameter that may 
modify interventions to direct targeted treatments and improve outcomes in traumatic 








Chapter 1: Introduction 
1.1 Overview 
 Traumatic brain injury (TBI) is a leading cause of death and disability among 
people in the United States. In 2010, a report by the Centers for Disease Control (CDC) 
estimated that of those diagnosed with a TBI, 87% (2,213,826) were treated and released 
from the emergency department, 11% (282,630) were admitted and then discharged, and 
2% (52,844) died.1 More than 3 million people in the United States are currently living 
with long-term disability from secondary injury related to TBI, and self-report a higher 
prevalence of activity limitation and reduction of life satisfaction, most notably in those 
who had suffered a severe TBI.2,3 Severe TBI, defined as Glasgow Coma Scale (GCS) of 
≤8, or motor score <5 if intubated, is associated with significant mortality and disability 
among survivors due to prolonged hospital stays and sequelae of secondary brain 
injury.4,5  
 Primary brain injury is defined as the direct mechanical forces that occur at the 
time of traumatic impact to brain tissue and include traumatic shearing and tearing of 
axons, diffuse axonal injury, and focal injuries such as intracranial hematomas.6,7 While 
primary brain injuries occur seconds to minutes after trauma, they trigger a cascade of 
secondary brain injury over time.8 Secondary brain injury may lead to the development of 
decreased cerebral blood flow, cerebral hypoxia, intracranial hypertension, and cerebral 
edema. It may also contribute to long-term complications, including seizures and the 
development of epilepsy, dysautonomia and behavioral disturbances in the ensuing days 
to months following the initial trauma.6,8,9  
1.2 Multimodal Monitoring in Traumatic Brain Injury 
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 Modern management of TBI is centered on multimodal monitoring of 
biochemical and physiological processes with the goal of identifying and preventing 
secondary brain injury, which can improve functional and cognitive outcome and reduce 
mortality.10,11 Although no single modality can recognize a detrimental physiologic event 
with complete certainty, the simultaneous use of multiple monitoring techniques has been 
accepted as an optimal strategy to guide treatments of TBI patients.10-13  
 When TBI occurs, intracranial hemorrhage or cerebral edema may cause a rise in 
intracranial pressure (ICP). ICP depends on a fixed ratio of volumes within the skull: 
brain parenchyma, cerebrospinal fluid (CSF), and blood. Based on the Monroe-Kellie 
Doctrine, this intracranial volume is stable and an increase in one volume is offset by a 
decrease in one or both of the remaining two.14 When compensatory mechanisms are 
intact, this principle describes the ability of the brain to manage small increases in 
volume without significant changes in ICP. However, when compensatory mechanisms 
fail, even small increases in volume result in increased ICP, decreased cerebral perfusion 
pressure (CPP), and reduced cerebral blood flow (CBF), which can compromise brain 
tissue perfusion and lead to ischemia.11,15 Elevated ICP has been shown to be highly 
predictive of mortality, and has been a focal point of monitoring and guiding TBI 
treatment in the current literature.16,17 Therefore, ICP monitoring is currently 
recommended by the Guidelines for the Management of Severe Traumatic Brain Injury in 
all patients with a severe TBI and an abnormal computed tomography (CT) scan 
revealing hematomas, contusions, swelling, or herniation.12,18 
 CPP is an important physiologic parameter that is often monitored simultaneously 
with ICP in the management of TBI. CPP is the difference between mean arterial 
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pressure (MAP) and ICP (CPP= MAP-ICP), and is therefore extrapolated from blood 
pressure and ICP measurements. It represents the pressure gradient driving CBF, which 
describes the extent to which oxygen and metabolites are being delivered to the brain 
tissue.11,12 Optimizing CPP ensures adequate perfusion and prevents brain tissue hypoxia 
(BTH) that may ultimately lead to ischemia.13 However, there is still uncertainty about 
whether management should be focused on CPP, ICP, or both, and if directing 
management towards one may be minimizing the importance of the other.13 Although a 
multimodal monitoring approach has been widely adopted as the optimal strategy in TBI 
care, there remains a lack of clinical consensus on specific monitoring modalities and 
treatment protocols that are informed by those values.11  
Table 1. Glasgow Coma Scale19  
 
Category Response Score 
Eye Opening Opens spontaneously  4 
 Opens to verbal stimulus 3 
 Opens to painful stimulus  2 
 No eye opening  1 
Best Verbal Response Oriented 5 
 Confused  4 
 Inappropriate  3 
 Incomprehensible  2 
 No verbal response  1 
Best Motor Response Obeys commands  6 
 Purposeful movement to painful stimulus  5 
 Withdraws from pain  4 
 Abnormal (spastic) flexion, decorticate posturing 3 
 Extensor (rigid) response, decerebrate posturing  2 
 No motor response  1 
 
1.3 Cerebral Oxygenation Monitoring    
 
 Cerebral oxygenation involves three main factors: CBF, arterial content of 
oxygen, and cerebral oxygen consumption.13 In TBI, an imbalance between oxygen 
delivery and consumption may ultimately lead to BTH.9 Increased incidence, duration, 
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and extent of BTH is associated with poor prognosis and functional outcomes; therefore, 
a critical goal of multimodal monitoring is to ensure sufficient perfusion and oxygenation 
of brain tissue.9 However, studies have shown that BTH is common in TBI and can occur 
even in the presence of normal ICP and CPP.8,18 This highlights the importance of an 
additional monitoring modality focused on cerebral oxygenation to supplement ICP and 
CPP monitoring, and necessitates that care of TBI patients without cerebral oxygenation 
incorporated into a multimodal monitoring approach is incomplete.6 
1.4 Limitations of Cerebral Oxygenation Monitoring 
 Prior studies have suggested that the addition of invasive brain tissue oxygenation 
(PbtO2) directed care in addition to the conventional ICP/CPP monitoring based 
management may be associated with reduced burden of BTH.20-22 Some studies have 
even suggested that management based on PbtO2 was associated with better short-term 
outcomes and was a better indicator of long-term prognosis than ICP and CPP 
management alone.23  
 However, obtaining PbtO2 requires an invasive monitoring technique that does 
not come without limitations and risk.11 Although PbtO2 catheters can be placed through 
a similar sized burr hole as an ICP monitor, they introduce post-surgical risk of infection 
and bleeding, and there is a need for precise placement for accurate measurements.24 
PbtO2 catheters only measure BTH regionally, and may provide vastly different data 
based on the location and depth that the catheter is placed in the brain parenchyma.24,25 
Placement on the more injured side of the brain may reflect the area most at risk for 
secondary injury, but will not provide an accurate assessment of the cerebral oxygenation 
in other areas. Alternatively, placement into a relatively healthy area of tissue may 
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provide a falsely reassuring value that is not indicative of potential hypoxia in more 
injured areas.24 Beyond its regional limitations, values are dependent on the patient’s 
blood CO2 and O2 concentrations, temperature, and hypermetabolic states such as fever, 
shivering and seizure activity.26-28 Therefore, a broader, noninvasive equivalent of 
cerebral oxygenation monitoring would make a substantial contribution for those whom 
invasive PbtO2 monitoring may be insufficient or introduce unnecessary risk.29 
1.5 Near Infrared Spectroscopy 
 Near infrared spectroscopy (NIRS) is a noninvasive monitoring modality suitable 
for continuous monitoring of surrogate changes in cerebral blood volume and cerebral 
oxygenation.11,30 Although similar in technology to pulse oximetry, which measures 
arterial oxygen saturation, NIRS measures tissue oxygen saturation, which consists of a 
combination of measures from arterial, venous, and capillary blood.31 The principle 
behind the technique is that infrared light is delivered via multiple emitters through the 
scalp and into brain tissue noninvasively and can detect cerebral oxygenation and 
measures of autoregulation on a global scale.32 Benefits of NIRS in the monitoring of 
cerebral oxygenation include that is that it is noninvasive, does not require frequent 
calibration, can be placed when an intracranial monitor may be unsafe, and minimizes the 
challenge of a constant and precise location of probes.33  
 NIRS monitoring in TBI patients provides distinct advantages through its 
noninvasive approach of detecting global rather than regional measures of cerebral 
oxygenation, has resistance to motion artifacts, and is flexible in location and patient 
positioning.34,35 In this way NIRS can be feasibly integrated into the clinical environment 
to directly monitor total hemoglobin, deoxyhemoglobin, and oxyhemoglobin, which 
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provides a parameter of cerebral oxygenation as well as a surrogate for measurement of 
CBF.36 
 NIRS technology is applied using various devices which quantify cerebral tissue 
oxygenation using equal (but device specific) indices such as tissue oxygen index (TOI), 
as measured by the NIRO2 200NX, or the cerebral oxygenation saturation (SctO2), as 
measured by CASMED-Foresight.37 Previous studies have shown that invasively 
measured PbtO2 and noninvasively measured TOI respond to changes in arterial pressure 
and ICP and that the direction of changes of TOI is concordant to that of PbtO2 in 77% of 
the analyzed events.38 A study by Suzuki, et al. compared TOI to a blood gas analyzer 
and showed excellent correlation between the two parameters, therefore validating its 
efficacy in clinical use.39 Furthermore, a study by Al-Rawi, et al. defined a drop in TOI 
(13%) based on NIRS that can be adopted as a threshold for identification of severe 
cerebral ischemia with high sensitivity and specificity.32 These data demonstrate the 
potential to identify NIRS derived thresholds for cerebral ischemia in the adult brain and 
support the use of NIRS cerebral oxygenation monitoring in a clinical setting.32  
1.6 Statement of the Problem 
  Use of ICP monitoring in severe TBI remains the gold standard in guiding 
treatment, and there is a well-described relationship between mortality and elevated ICP 
after TBI. However, there is still no large randomized clinical trial confirming its 
effectiveness in guiding management, and to date there is no Level 1 clinical evidence 
proving its mortality benefit. Additionally, ICP monitoring facilitates calculating the CPP 
through the relationship that CPP= MAP-ICP. Similar to NIRS, ICP monitoring allows 
for surrogate measures of cerebral perfusion. Optimal ICP or CPP thresholds have yet to 
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be determined, and there is still debate over whether management of patients should be 
targeted towards ICP or CPP as the main physiologic determinant.13,23 Once the primary 
injury has occurred, therapy is directed towards preventing secondary brain injury by 
ensuring the adequate delivery of oxygenated blood and nutrients to brain tissue to 
minimize the risk of supply-demand mismatch. Prior studies have suggested that reduced 
duration of BTH is associated with lower mortality rates, but authors acknowledge that 
using PbtO2 as a monitoring technique has limitations. Monitoring with PbtO2 reflects a 
regional rather than a global measure of cerebral oxygenation and requires an invasive 
surgical procedure for placement of the catheter.12,18,40-42 NIRS as a noninvasive modality 
of monitoring cerebral oxygenation has shown promise, but a larger randomized clinical 
trial in TBI is necessary to provide definitive evidence of its benefit.10,29,43 
 Authors agree that the absence of sufficiently powered prospective studies and 
clinical trials investigating the efficacy of these modalities has resulted in a lack of 
clinical consensus in the monitoring algorithm of TBI. There has yet to be a functional 
integration of all of these modalities that allow clinicians to make informed decisions 
regarding management and intervention.10 Given the limitations of the current literature 
and lack of definitive clinical data, further clinical trials are vital to establish optimal 
methods and establish a standard of care among providers. Our proposed study will help 
to clarify the clinical utility of noninvasive cerebral oxygenation monitoring as a 
surrogate for cerebral perfusion in reducing BTH and whether its integration into the 
multimodal monitoring approach is warranted to guide TBI treatment. 
1.7 Goals and Objectives 
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 Our proposed multicenter randomized controlled trial (RCT) aims to determine 
whether cerebral oxygenation monitoring by NIRS can reduce the burden of BTH and be 
incorporated into a standardized multimodal monitoring approach to guiding treatment of 
severe TBI. The primary outcome will be to determine if treatment guided by cerebral 
oxygenation monitoring with NIRS in addition to ICP monitoring can reduce the median 
duration of BTH in the first 72 hours of injury as compared to ICP monitoring alone. This 
outcome will determine the efficacy of NIRS as a monitoring modality in guiding clinical 
decision making based on brain tissue oxygenation.  
 Our secondary outcome will be to determine functional outcome in each of our 
groups at 6 months post initial injury utilizing the Glasgow Outcome Scale-Extended 
(GOS-E) on an 8-point rating system. This information will determine whether the NIRS 
based interventions improve functional outcome. 
1.8 Hypothesis  
 We hypothesize that goal directed therapy based on brain tissue oxygenation 
monitoring by NIRS plus ICP monitoring will show a difference in median duration of 
brain tissue hypoxia over 72 hours, as compared to therapy guided by ICP monitoring 
alone in the treatment of adults with severe traumatic brain injury.  
1.9 Definitions 
Median duration of BTH: median duration of time spent below threshold, defined as 
SctO2 ≤ 50%, continuously measured and transmitted at 5 minute intervals over a 72 
hour span.  
Goal directed therapy: predetermined treatment protocol directed at a set combination of 
physiological interventions that will address elevated ICP alone, or BTH and elevated 
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Chapter 2: Review of the Literature 
2.1 Introduction- Literature Search Criteria  
 A thorough review of the literature was conducted between July 2019 and April 
2020 using Ovid Medline, Embase, Cochrane Medical Library and Pubmed. Only 
English language articles were evaluated. Review of titles and abstracts determined 
relevance to the proposed study for analysis. Key terms used independently or in 
combination to search each database included: traumatic brain injury, severe traumatic 
brain injury, monitoring, neurophysiological monitoring, intracranial pressure, cerebral 
oxygenation, brain tissue oxygenation, near infrared spectroscopy, cerebral perfusion 
pressure, autoregulation, brain tissue hypoxia, intracranial hypertension, Glasgow Coma 
Scale, Glasgow Outcome Scale, Glasgow Outcome Scale Extended, IMPACT, CRASH, 
functional outcome, and disability. Most clinical studies reviewed were observational in 
nature, but a few influential RCTs were identified. Their analysis and review in relation 
to our proposed study are detailed below.   
2.2 Overview of Traumatic Brain Injury  
 TBI is caused by a blunt force, blast or penetrating wound that disrupts the normal 
function of the brain.1 TBI has a range of short and long-term clinical outcomes including 
cognitive and psychological impairments, functional disability, and death.1 Currently, 
TBI severity is classified by the 15-point GCS based on a patients level of consciousness 
and assessed by verbal, motor and eye opening response.2 Patients are then further 
categorized into ranges from mild (GCS score 13-15), moderate (9-12) and severe (3-
8).2,3 Recovery from TBI and return to baseline function is dependent on a complex 
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pathophysiology that includes biochemical and cerebral metabolic disruptions, diffuse 
axonal injury, hemorrhagic contusions, cerebral edema, and BTH, among others.3-5  
 In the prehospital and emergency room setting after TBI, the focus is on 
resuscitating and supporting the primary brain injury, which is caused by the direct 
mechanical forces of traumatic impact to brain tissue.2,4 Once a patient is transferred to 
the intensive care unit (ICU), the effort shifts towards stabilization of hemodynamics and 
systemic oxygenation to prevent secondary brain injury.4 Secondary brain injury can 
result in irreversible damage if undetected; thus the goal is detecting it when there is still 
time to intervene.6 Utilizing various physiological monitors, patient care is centered on 
identification and management of secondary brain injuries that evolve in the hours to 
days following the primary injury, which requires careful monitoring of cranial and 
systemic physiology throughout their ICU stay.7-9 
2.3 Review of Current Monitoring Strategies in Traumatic Brain Injury 
 Use of monitoring in TBI has been used for decades and is considered the basis 
from which we guide our treatment. However, it is not the monitoring alone that affects 
patient outcomes, but the ability to use that information to guide goal directed therapy. 
There is no single monitoring modality that can guide management with complete 
certainty, but use of a multimodal approach has been accepted as the optimal strategy in 
maintaining cerebral physiology, improving functional outcomes, and reducing mortality 
rates.6,10-12 It is widely believed that treatment informed by data from monitoring may 
result in better outcomes than treatment informed solely by clinical assessment, as 
patients with severe TBI are comatose. However, to date there have been no large RCTs 
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confirming which monitoring modalities alone, or in combination, provide superior 
guidance in directing therapy in TBI.10  
2.3.1 Intracranial Pressure Monitoring 
 ICP monitoring has been the focal point of physiological monitoring in TBI care, 
and is currently recommended by the Guidelines for the Management of Severe 
Traumatic Brain Injury for all salvageable patients with a severe TBI and an abnormal 
CT scan.10  
 In 2013, Alali, et al. conducted an observational retrospective cohort throughout 
the United States and Canada from 2009-2011 that examined the relationship between 
invasive ICP monitoring and in-hospital mortality. The study identified a large population 
of patients with severe TBI who met the guidelines for ICP monitoring and compared 
those who received ICP monitoring with those that did not.10 Data from more than 10,000 
patients and 155 centers were utilized in determining that ICP monitoring was associated 
with significantly lower odds of in-hospital mortality at the patient level (adjusted OR, 
0.44; 95% confidence interval [CI] 0.31–0.63; p < 0.0001).13Although the large sample 
size of this study provides external validity and is generalizable in the United States, 
treatments based on monitoring were not controlled for, and details about those specific 
protocols were not reported. Internal validity suffers due to the observational nature of 
the study, and the authors admit to large variability of care among institutions at the 
hospital level. This variability was thought to be due to treatment differences based on 
clinical judgments of prognosis, which makes it more difficult to attribute success to ICP 
monitoring guided treatment alone on a larger scale.10,13  
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 A 2013 prospective observational study by Talving, et al. studied a similar 
population of 216 severe TBI patients who met the Brain Trauma Foundation’s (BTF) 
criteria for ICP monitoring, and observed rates of in-hospital mortality and length of 
stay.14 Their results supported Alali, et al. in their findings that ICP monitoring was an 
independent predictor of overall in-hospital mortality, (adjusted OR 0.13 [95% CI 0.02–
0.81], p = 0.029) and showed a significant reduction in mean hospital length of stay by    
-9.26 days (95% CI [-13.10 to -5.42], p <0.001). However, similarly to the study by Alali, 
et al., the treatment protocol informed by ICP monitoring was not controlled for or 
documented and was based on physician discretion, which introduces selection and 
information bias. Additionally, the study’s external validity suffers due to the fact that it 
was conducted at a single medical center.14 
 Additional retrospective cohort studies by Farahvar, et al. in 2012 and Gerber, et 
al. in 2015 examined the relationship of ICP monitoring in TBI and 2-week in-hospital 
mortality rates.15,16 Although both studies found a significant relationship to reduced 2-
week in-hospital mortality rates with ICP monitoring, there are concerns with both 
designs. Farahvar, et al. identified their population retrospectively based on patients who 
received ICP lowering treatments based on their clinical presentation, and then followed 
their course from that point on to determine benefit.15 This design is problematic in that 
they examined outcomes, but did not offer insight into how the monitoring itself, if 
initiated at baseline, would guide treatment.15 Although the mortality rate for those 
treated with an ICP monitor was 19.6% (n=212), compared with 33.2% (n=74) in those 
treated without an ICP monitor, the question remains whether or not physicians decided 
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not to monitor those patients whose condition was considered more severe and potentially 
not salvageable, introducing bias.15  
 Although the findings were similar for Gerber, et al., their primary outcome was 
mortality based on adherence to guidelines for ICP monitoring, which varied among 
institutions and included guidelines for other factors. They studied severe TBI patients in 
New York State from 2001-2009 and found that based on guideline adherence, 55.6% of 
patients from 2001-2003 had ICP monitoring, which increased to 75.2% between 2007 
and 2009 (p < 0.0001). There was also a significant association between mortality and 
ICP monitoring compliance such that mortality in the noncompliance group was 25.8% 
versus 18.6% in the compliance group (p=0.0002). However, it is difficult to establish 
causality in this relationship due to the advances in other aspects of TBI monitoring and 
care over that time period, and significant variability among patient demographics.16 
 Considering that ICP monitoring has been the standard of care in the BTF 
guidelines for management of severe TBI, most evidence in support of ICP monitoring 
has been observational in nature.10,13-16 A 2012 multicenter RCT by Chesnut, et al. 
challenged this evidence by randomizing patients to protocols to treat intracranial 
hypertension (ICH) (pathologically elevated ICP) based on either an invasive ICP 
monitor or by clinical/radiological examination alone. 324 patients aged 13 or older in 
Bolivia and Ecuador were randomized to receive either invasive ICP monitors or imaging 
and clinical examination alone. Randomization was stratified according to study site, se- 
verity of injury, and age, and was conducted at 6 hospitals throughout Bolivia and 
Ecuador that received a high volume of trauma patients. Their primary hypothesis was 
that a management protocol based on ICP monitoring would result in reduced mortality 
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and improved functional outcome as measured by GOS-E at 6 months compared to 
management based on clinical/radiological evidence alone. Primary outcome was 
survival and functional outcome as assessed by GOS-E at 6 months, and secondary 
outcome was hospital length of stay.17  
 In contrast to findings by prior observational studies, the authors found that there 
was no significant between-group difference in the functional and cognitive status based 
on GOS-E (score of 56 in the ICP monitoring group vs. 53 in the imaging/clinical 
examination group; p=0.49). Additionally, 6-month mortality was similar at 39% in the 
ICP monitoring group and 41% in the imaging/clinical examination group (p=0.60), and 
median length of stay in the ICU was similar in the two groups (12 days in the ICP 
monitoring group and 9 days in the imaging/clinical examination group (p=0.25))17  
 As the only standardized, class 1 RCT providing evidence for ICP monitoring, 
this study had excellent internal validity. The results were not significant to refute the use 
of ICP monitoring and will not change the current recommended guidelines. However, 
this contributes to the uncertainty of multimodal monitoring strategies in TBI care and 
calls for additional research into a standardized algorithm of multimodal monitoring that 
is proven beneficial to TBI management.  
2.3.2 Cerebral Perfusion Pressure Monitoring 
 Over the past decade, emphasis has been placed on optimizing CPP in addition to 
ICP in TBI. CPP is a surrogate for CBF and is the difference between systemic MAP and 
ICP.10-12,18 CPP is directly influenced by ICP and MAP and can change based on 
alterations in either physiologic variable. Ensuring CPP is adequate in an injured brain is 
integral to maintaining sufficient blood flow and reducing secondary brain injury. 
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Decreased MAP, elevated ICP, and the resulting decreased CBF can result in tissue 
ischemia and infarction, supporting the importance of CPP in monitoring.19 However, the 
question remains whether CPP monitoring alone, or in combination with other modalities 
can provide the optimal guidelines for management of severe TBI. 
 The first assessment of CPP monitoring in the management of TBI was a 1990 
prospective study by Rosner, et al. in 34 patients with severe TBI (defined here as GCS ≤ 
7). Their primary hypothesis was that CPP actively maintained between 70-80 mmHg 
would improve mortality and outcomes based on the GOS. Their results showed a 
mortality rate of 21%, and “good recovery rate” of 68%, based on their categorical scale 
informed by GOS.20 Although the study had a small sample size and was conducted at a 
single institution, it was the first study examining CPP as a physiological monitoring 
parameter, established a reference range, and provided a necessary outline for 
management protocols going forward. 
 A more recent retrospective cohort by Gerber, et al. in 2013 evaluated CPP 
monitoring in severe TBI, whose findings were previously discussed in the analysis of 
ICP monitoring. Not only did they analyze guideline adherence and mortality rates for 
ICP monitoring, but for independent CPP monitoring as well. In New York State from 
2001 to 2009, adherence to CPP treatment thresholds increased significantly from 14.6% 
in 2001-2003 to 48.2% in 2009 (p<0.0001). CPP monitoring compliance was associated 
with decreases in ICH (10.1% in the CPP noncompliance group in 2007-2009 versus 
40.9% in 2007-2009 compliance group, p<0.0001). As mentioned previously, mortality 
rates dropped significantly over this time period and correlated with significantly 
increased adherence to CPP monitoring, as well as ICP monitoring.16  
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 These results suggest a role in CPP monitoring in the reduction of mortality in TBI 
management. Not only did CPP monitoring adherence independently improve mortality 
rates, but the fact that ICH improved when CPP was elevated indicates that ICP and CPP 
monitoring together can contribute to mortality benefit.  Strengths of the study include its 
large sample size, multiple sites and duration. However, the study took place only in New 
York, which reduces its generalizability to a larger population, and the authors admit that 
variability among sites and patient demographics is significant. As discussed previously, 
although there is a strong correlation with CPP monitoring and reduction of ICH and 
mortality, it is difficult to prove causality.  
 A 2006 retrospective analysis by Huang, et al. studied 376 patients with severe 
TBI over a 12-year period in Taiwan. Their main goal was to evaluate the efficacy of 
management based on: a) ICP monitoring, b) CPP monitoring (CPP target >70 mmHg), 
and c) CPP modified monitoring (mCPP) (CPP target >60 mmHg). Primary outcome was 
functional status as assessed by GOS at 6 months, in which favorable was defined as 
good recovery or moderate disability and unfavorable was defined as severe disability or 
vegetative state. Among the sample, 77 were in the CPP targeted group and each group 
was well balanced based on injury severity and demographics.   
 Results showed that mortality rates in the ICP only group were significantly 
higher than in the CPP or mCPP groups (28.6% in ICP, 14.3% in CPP, and 13.5% in 
mCPP, p=0.02 and p=0.03 respectively). In the CPP directed group, the percentage of 
unfavorable outcomes was 22.1% and the percentage of favorable outcomes was 63.6%, 
while in the ICP group the percentage of unfavorable outcomes was 22.7% and the 
percentage of favorable outcomes was 48.8%. Not only was there a statistically 
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significant reduction in mortality in both CPP groups versus the ICP group, but favorable 
outcome in the ICP group was also significantly lower than in the CPP and mCPP groups 
(p=0.04 and p=0.01, respectively). There was no significant difference between the two 
CPP directed groups, but both showed significant benefit versus the ICP only group.21 
These results suggest that a CPP targeted regimen is actually preferable over an ICP only 
regimen in the guidance of treatment for TBI.  
 Although the results of Huang, et al. are initially convincing, the study lacks 
internal validity due to its retrospective nature and lacks generalizability to the US 
population. The authors also admit that poor outcomes in the ICP group may have been 
attributed to poor clinical management strategies to lower ICP during this time period, 
which have been modernized and improved in the time since. Ultimately, the question of 
whether management should be directed towards CPP or ICP is still a matter of debate, as 
directing management towards one parameter may be minimizing the importance of the 
other.12 
2.3.3 Brain Tissue Hypoxia 
 BTH is a common cause of secondary brain injury after severe TBI.22,23 Increased 
BTH incidence, duration, and extent is associated with poor outcomes, and may result 
even when ICP and CPP are maintained within targeted thresholds.22,24-26 Efforts to 
maintain adequate cerebral oxygenation is therefore an important aspect of TBI 
management and has been a topic recently addressed in the literature.  
 A systematic review conducted by Maloney-Wilensky, et al. in 2009 examined 
three prior prospective observational studies that evaluated BTH and outcome based on 
mortality and GOS scores at 6 months.27 Collectively, 71 out of 150 (47%) patients met 
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the criteria for BTH, which was defined as brain tissue oxygen (BtO2) <10 mmHg 
(measured regionally by a direct brain oxygen probe) and was standardized across all 
three studies. Among those patients with BTH, 52 (73%) had an unfavorable outcome as 
determined by GOS, and 39 (55%) died. In the absence of BTH, only 34 (43%) had 
unfavorable outcome, and 17 patients died (22%). Overall, in patients who experienced 
BTH (BtO2 <10 mmHg for >15 minutes), the odds ratio (OR) of unfavorable outcome 
(death and disability) at 6 months was 4.00 (95% CI [1.9 – 8.2]), and the OR of death at 6 
months was 4.6 (95% CI [2.2–9.6]), suggesting that BTH is significantly associated with 
poor outcome after severe TBI.26,28,29 
 However, there are limitations to conclusions drawn from this data based on the 
studies included. Considering that these studies were observational in nature, internal 
validity suffers. The authors also admit that these studies may have been subject to bias 
based on how risk factors for outcome were controlled. Additionally, differences in 
where monitors were placed, when the GCS was recorded, or how frequently data were 
obtained varied and may bias the results. But ultimately, the two major variables of 
concern, outcome and GCS, were similar across studies and the findings are consistent 
among the literature.27  
2.3.4 Invasive Cerebral Oxygenation Monitoring 
 An attempt to establish a relationship between BTH, invasive cerebral 
oxygenation monitoring and outcome was conducted in a 2009 retrospective cohort study 
by Martini, et al. between 2004 and 2007. The study included 629 patients admitted with 
diagnosis of severe TBI at a single Level 1 Trauma Center in Seattle, WA. Their primary 
goal was to determine how clinical management based on PbtO2 monitoring affected 
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mortality rates, neurological outcome (as measured by Functional Independence Measure 
[FIM]), and resource utilization in this population. The entire population received ICP 
monitoring, but 506 received ICP monitoring alone, while 123 received ICP monitoring 
plus invasive cerebral oxygenation monitoring with PbtO2. The study found that there 
was no observed reduction in hospital mortality rate with management guided by the 
ICP/PbtO2 monitored group (29%) versus the ICP only group (23%). Even more 
surprising is that in patients who survived, the likelihood of a good neurological outcome 
(FIM≥ 7, which is defined as some level of independence) was actually smaller in the 
ICP/PbtO2 monitored group (7.6 ± 3.0) versus 8.6 ± 2.8 in the ICP monitored group (p < 
0.01). After adjustment, there was a significant, -0.75 (95% CI -1.41 to -0.09) point 
reduction in mean FIM scores in patients with PbtO2 monitors versus ICP monitors 
alone.30 
 Although this data seemingly contradicts earlier observations in the literature 
regarding BTH and neurological and functional outcomes, there are significant flaws in 
the study design and protocol that reduce its applicability. The observational nature of the 
study and its single location had limitations on internal validity, and there was an 
additional possibility that patients in the PbtO2/ICP group had a different initial 
prognosis than those in the ICP group. In fact, patients in the ICP/PbtO2 group on 
average were younger (35.7± 16.9 years) and had more severe brain injuries (GCS 5.1  
±2.2) than in the ICP only group (40.7±19.6 years, GCS 5.6 ±2.3). The study reported 
that as a result, patients in the PbtO2/ICP group received more aggressive management 
and may have experienced serious adverse events. Finally, authors admit that the sample 
size of each group was significantly different (n=506 in ICP monitoring group, n=123 in 
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the ICP/PbtO2 monitoring group) and may have influenced results, and that the residual 
confounding that was possible in their study warrants an RCT to better investigate the 
relationship.30  
 In opposition to results concluded by Martini, et al., two retrospective analyses by 
Oddo, et al. in 2011 and Narotam, et al. in 2009 found a significant reduction in BTH and 
improved functional outcomes with management protocols guided by PbtO2.23,31 When 
30-day outcomes were assessed, Oddo, et al. found that BTH (defined as PbtO2<15 
mmHg) was longer in duration in patients with unfavorable outcomes (GOS 1-3, 
8.3±15.19 hours) than in those with favorable outcomes (GOS 4-5, 1.7 ±3.7 hours, 
p<0.01).23 When compared to an ICP plus CPP monitoring group, Narotam, et al. found 
that management based on PbtO2 alone showed a significant reduction in BTH, mortality 
rate and better long-term outcomes when evaluating GOS at 6 months. There was a 44% 
improvement in mean BTH in the PbtO2 group (23.65 mmHg ± 14.40 mmHg) versus the 
ICP/CPP group (16.21 mmHg ± 12.30; p < 0.001). Results also supported better 
functional outcomes at 6 months in the PbtO2 group (GOS of 3.55 ± 1.75 versus 2.71 ± 
1.65, p < 0.01; OR for good outcome 2.09, 95% CI [1.031- 4.24]). 31 Each of these 
studies concluded that functional outcomes were better and mortality rates were lower 
with decreased burden of BTH. Additionally, they reported that BTH was possible even 
in the presence of normal ICP and CPP; and in the case of Oddo, et al., determined that a 
management strategy based on PbtO2 alone was actually superior in preventing BTH 
than in a protocol based on CPP and ICP in combination.23,31  
 In 2017, a two-arm, single blind, prospective randomized controlled multicenter 
trial by Okonkwo, et al. (BOOST-II) evaluated the relationship of management guided by 
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PbtO2 monitoring in severe TBI and functional outcome and mortality. Their main 
hypothesis was that in patients with severe TBI, a management protocol informed by 
PbtO2 and ICP values would reduce the total burden of BTH. 119 severe TBI patients 
who met the BTF criteria for ICP monitoring were randomized to ICP monitoring only 
(n=62) or ICP plus PbtO2 monitoring (n= 57), with patient demographics and injury 
severity remaining similar among groups. Each patient enrolled, regardless of 
randomization, was treated based on a tiered management protocol derived from the 
Guidelines for the Management of Severe Traumatic Brain Injury and informed by values 
indicated by their monitoring modalities.10  
 Results opposed Martini, et al. in that management for episodes of hypoxia based 
on PbtO2 resulted in significantly less BTH (as measured by median proportion of time 
below 20 mmHg) in the ICP+PbtO2 group (median .07) versus median .45 in the ICP 
only group (p= 0.0000147). Additionally, 6-month GOS-E scores trended towards lower 
mortality and better functional outcome in the ICP+ PbtO2 group with 25% mortality 
versus 34% mortality in the ICP only group, although those results were not significant 
due to limitations of sample size. At the 6-month evaluation checkpoint, 11% more 
patients in the ICP+PbtO2 group achieved favorable outcomes (GOS-E of 5-8) than in 
the ICP group, indicating improved recovery and return to functional status. In 
conclusion, we can reasonably state that these results confirm the safety and feasibility of 
a management protocol based on PbtO2 monitoring. BOOST-II also refutes Martini, et al. 
and supports the hypothesis that PbtO2 directed therapy can mitigate secondary brain 
injury by reducing BTH in severe TBI and can serve as a framework for future RCTs to 
examine this association.  
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 Although the results of BOOST-II are convincing in their support of PbtO2 plus 
ICP monitoring as an optimal strategy in guiding TBI management, there are still 
limitations to the study design. Most significantly, the study did not recruit a sample size 
sufficient to power results for clinical efficacy, but rather for a safety and feasibility 
outcome. This was intentional by the authors, indicating that BOOST-II was a Phase II 
trial confirming the safety and feasibility of their clinical protocol. Additionally, the 
results trended towards lower mortality and better GOS-E scores at 6 months, but were 
not significant due to limitations of sample size.25 Both of these flaws are the result of 
being insufficiently powered, which can be addressed in a future RCT examining this 
relationship. BOOST-III, which is now underway, will examine the impact of ICP 
monitoring vs. ICP+PbtO2 monitoring on outcome in a study powered for clinical 
efficacy.  
2.3.5 Near Infrared Spectroscopy in Cerebral Oxygenation Monitoring 
 Cerebral NIRS measures cerebral oxygenation by indirectly measuring the 
metabolic state of the brain tissue.6 It represents an exciting and novel approach to 
noninvasive measurement of cerebral oxygenation across many spectrums, including 
TBI.  
 Considering the current lack of clinical evidence for NIRS in adults with TBI, 
correlation with existing modalities of cerebral oxygenation monitoring, such as PbtO2, 
is necessary. In a 2012 retrospective analysis by Budohoski, et al., NIRS based 
parameters of cerebral oxygenation were shown to have a significant temporal 
relationship to PbtO2 and ICP. The goal of the study was to observe and categorize 
cerebral oxygenation and perfusion in 42 TBI patients with PbtO2 and NIRS monitoring 
 26 
across a range of ICP and arterial blood pressures. The authors hypothesized that PbtO2 
and NIRS could reliably monitor cerebral oxygenation but differed in their reaction times 
to patterns of change in arterial pressure and ICP.  
 Results indicated that the direction of change of each modality was similar, but 
NIRS reacted first to arterial pressure and ICP fluctuations, while PbtO2 showed a 
delayed response. These results indicate that the modalities both reliably measure 
changes in cerebral oxygenation but react on a different temporal scale. Among 25 
occurrences of ICP fluctuation, there was a significant difference in latencies of detection 
of events between PbtO2 and NIRS (p=0.04), but a consistent direction of change 
between the two modalities. In arterial pressure fluctuations (96 events), there were 
significant temporal differences between NIRS and PbtO2 detection (p<0.001), but again, 
the majority in the same direction.  
 Overall, results indicate that with impaired cerebrovascular reactivity (ICP and 
arterial pressure fluctuations), NIRS parameters and PbtO2 were concordant in 77% of 
events.32 However, the retrospective and observational nature of the study limits its 
internal validity. Although there is significant correlation between arterial pressure, ICP 
and cerebral oxygenation (measured by NIRS and PbtO2), it does not provide proof of 
causality. These results are important in establishing the relationship between PbtO2 and 
NIRS and provide evidence that NIRS can be utilized in cerebral oxygenation monitoring 
in TBI similarly to the way PbtO2 has been in previous trials, but the need for a large 
RCT establishing this relationship is clear. 
 In addition to cerebral oxygenation, NIRS can be used as a noninvasive method 
for continuous detection of cerebral blood volume as a marker of cerebral autoregulation. 
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Cerebrovascular pressure reactivity (PRx) is the capability of cerebrovascular smooth 
muscle to react to changes in transmural pressure. Autoregulation is the maintenance of 
cerebral blood flow over a wide range of arterial blood pressure, based on changes in 
resistance to cerebral vasculature.10 PRx, therefore, is the index by which autoregulation 
can be measured, and is calculated using CPP (MAP-ICP), which requires invasive ICP 
monitoring and continuous assessment of arterial blood pressure. Alternatively, using a 
noninvasive NIRS based index of cerebrovascular reactivity called total hemoglobin 
reactivity (THx), one study hypothesized that continuous recording would correlate with 
PRx and provide similar information about optimal arterial blood pressure and CPP in 
ensuring adequate autoregulatory status in TBI.  
 In this prospective observational study by Zweifel, et al., 40 patients with TBI 
were recorded 120 times daily using either NIRS to determine THx or invasive ICP 
monitoring to derive PRx. Authors found a significant correlation between PRx and THx 
indices (r=0.49, p<0.0001) across averaged individual recordings, which increased to 
r=0.65, p<0.0001 when patients with possible confounding factors were excluded.33 
These results indicate that NIRS derived indices of autoregulation (THx) can be used as a 
noninvasive alternative to determine optimal CPP and MAP in TBI patients. Although 
significant, data was obtained from a single site with limited sample size, which limits 
external validity. In their review, Davies, et al. mentioned that only events where changes 
in ICP resulted in a significant change in THx were considered for analysis. It is possible 
then that there were significant events of elevations in ICP that evoked no change in 
NIRS parameters.34 Additionally, correlation increased between the two techniques when 
patients with frontal contusions were excluded, indicating the possibility that superficial 
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contusions or hematomas on the scalp may interfere with NIRS signal acquisition, a 
major limitation in TBI patients. However, this method may be particularly beneficial in 
patients whom invasive monitoring is contraindicated, unavailable or poses unacceptable 
risk. This study adds clinical significance to the utility of NIRS for measurement of 
autoregulation in addition to cerebral oxygenation.  
 A 2015 Phase II RCT by Hyttel-Sorensen, et al. evaluated the influence of NIRS 
monitoring on treatment guidelines in 166 preterm infants. Their primary hypothesis was 
that the burden of BTH could be reduced by a treatment guideline informed by cerebral 
NIRS monitoring.35 During the first 72 hours of life, infants were randomized to cerebral 
oxygenation monitoring with NIRS (n=86) or blinded monitoring (n=80), in which their 
treatment would be dependent upon. Their primary outcome measure was BTH as 
measured by time spent outside of a defined target cerebral oxygen range and expressed 
in percent hours; and secondary outcome was defined as all-cause mortality. 
 Results concluded that the 86 infants randomized to NIRS monitoring had a 
significantly reduced median duration of BTH (16.6% hours [IQR 5.4-68.1%]) compared 
to the blinded group (53.6% hours [IQR 17.4-171.3]; p=0.0012), and a trend towards 
reduced all-cause mortality, although results were not significant. These results indicate 
that NIRS cerebral oxygenation monitoring can be successfully utilized to guide a 
treatment protocol to significantly reduce burden of BTH without the risk of serious 
adverse events.35  
 A major limitation of this study was clearly the population of interest and lack of 
generalizability, in that these patients were premature infants and did not suffer a TBI. 
The authors also admit that there was variability in the delivery of treatment protocols 
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due to inconsistent clinical discretion of the healthcare team among different sites, and 
that complete blinding of group allocation to the staff was not possible. Although there 
are limitations to the study, this was the first multicenter RCT in analysis of NIRS in a 
human population and showed promising results in its applicability for clinical use. 
While results indicate that this technology can be successfully utilized in human patients, 
a review by Davies, et al. pointed out that cerebral NIRS is a more established modality 
in neonatal intensive care due to favorable anatomical factors in the population such as 
decreased skull thickness.34,36 Reflecting the opinions of other authors, Davies, et al. call 
for large cohort prospective clinical trials to demonstrate the optimal use and clinical 
efficacy of NIRS monitoring in the adult TBI population.  
2.4 Review of Prognostic Indicators  
 In order to predict the risk of unfavorable outcomes or death in patients with 
severe TBI, baseline prognostic models have been created that correlate significantly with 
6-month GOS-E scores. The International Mission on Prognosis and Analysis of Clinical 
Trials (IMPACT) study gathered data from 9,205 patients with moderate and severe TBI 
(defined as GCS ≤12) from eight RCTs and three observational studies between 1984 and 
1997.37 Prognostic scoring algorithms were then derived from the IMPACT study by 
Steyerberg, et al., and were found to have individual statistical significance in correlating 
to GOS-E 6-month outcome scores. The baseline characteristics used in calculating 
prognosis are obtained at initial presentation, which allows for application of the model 
before in-hospital therapeutic interventions.38 Baseline characteristics in the IMPACT 
prognostic lab model include: demographics (age, sex, race), indicators of clinical 
severity (cause of injury, GCS components, pupillary reactivity), secondary insults 
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(hypoxia, hypotension, hypothermia), blood pressure, Marshall CT classification,39 
presence of intracranial hematomas, glucose, and hemoglobin at time of admission.38 The 
IMPACT core model is an abbreviated adaptation of the lab model that is composed of 
age, GCS motor score, and pupillary reactivity and has been utilized in studies such as 
BOOST-II to control for prognostic indicators of clinical severity between control and 
intervention groups.25,38  
Table 2. IMPACT Core Model Prognostic Indicator37,38 
Characteristics Value Score 
Age (years) ≤ 30 0 
 30-39 1 
 40-49 2 
 50-59 3 
 60-69 4 
 70+ 5 
Motor Score None/extension 6 
 Abnormal flexion 4 
 Normal flexion 2 
 Localizes/obeys commands 0 
 Untestable/missing 3 
Pupillary reactivity Both pupils reactive 0 
 One pupil reactive 2 
 No pupil reactive 4 
Sum Score Core Model   
 
 A 2012 external validation study by Roozenbeek, et al. confirmed that the 
IMPACT prognostic model was generalizable and can be reasonably applicable to 
classify TBI patient populations based on prognostic risk, which may be ultimately 
indicative of GOS-E outcome scores.40 In our proposed study, IMPACT core model 
scores will be obtained and matched between groups in order to reduce the imbalance of 
important prognostic indicators, and then compared to GOS-E outcome at the completion 
of the trial.  
2.5 Review of Relevant Methodology 
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 This section will briefly review relevant methodology of the studies reviewed 
above to further validate our proposed study design and designation of methods.  
2.5.1 Review of Studies to Identify Possible Confounding Variables 
  Most studies that investigate the clinical utility of monitoring modalities in TBI 
care employ observational studies to obtain their data. This type of study design is 
appropriate when there is a standard of care, such as ICP monitoring, which is being 
investigated or modified.10 Most studies included in review, despite a select few seminal 
RCTs, have utilized observational studies to make conclusions about their hypothesized 
associations. Although almost all studies reach statistical significance in some outcome, 
potential confounding variables to their study designs will be reviewed.   
 Large retrospective observational cohorts are beneficial in analyzing a large 
sample with high external validity but are susceptible to confounding by uncontrolled 
variables. Several confounders were controlled for consistently among reviewed studies 
to reduce this effect, including gender, race, comorbid illnesses, injury mechanism and 
severity, type of intracranial lesion, and vital signs (including GCS) in the emergency 
department and during hospital stay. But authors admit that physician judgment, the 
course of the patient during the hospital stay, and the lack of availability of trained staff 
were all possible confounders that they could not reasonably control in this type of study 
design.13 A widespread issue among observational studies included in review is the 
inability to control for physician biases or preferences, in that they may decide to place a 
particular monitor or not in patients because of an anticipated favorable or unfavorable 
outcome.13-16 As Farahvar, et al. explain, to determine why some patients were treated or 
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not, and the decision behind it, is beyond the scope of their study and is a topic requiring 
investigation.15  
 A prospective, observational study by Talving, et al. attempted to reduce bias 
from confounding factors by utilizing propensity matching; a technique that tries to 
estimate the effect of a treatment by accounting for the covariates that predict receiving 
the treatment.14 This technique specifically addressed the issue of physician bias in the 
decision to treat, or not. Regardless, a major issue in an observational design is that even 
when the decision is made to place a monitor or not, treatment regimens were largely 
dependent on clinical judgment. Physician discretion ultimately determined treatment 
plans, and it was possible that patients with ICP monitors were treated more aggressively 
than those without.14 In fact, the retrospective cohort by Martini, et al. did collect 
information on patient demographics in each arm of their study (ICP monitoring alone 
versus ICP plus PbtO2 monitoring), and found that there was bias in decision to treat. 
Patients in the intervention group (ICP plus PbtO2 monitoring) on average were younger 
and had more severe brain injuries than in the control group (ICP monitoring only), and 
consequently received more aggressive management.30 The opposite was observed in a 
single site retrospective analysis by Budohoski, et al., where treatment protocols were 
well established but patient characteristics varied. Although the treatment protocol was 
controlled for, sample size was small, and patient characteristics were significantly 
different (including injury type and severity based on GCS). Similarly to a study by 
Oddo, et al., the authors admit that confounding was possible based on the variable 
placement/location of devices, and the variable duration of monitoring among 
patients.23,32 It is clear from the studies reviewed that management of severe TBI is 
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complex and multifaceted, and RCTs are necessary to control for patient demographics, 
monitoring protocols, and treatment algorithms within each study design. 
 In a review of RCTs, efforts were made to reduce confounding by creating 
guidelines for randomization and an established treatment protocol based on each 
treatment arm.17,25,35 Despite this, a RCT by Hyttel-Sorensen, et al. still found that 
implementing treatment protocols based on NIRS monitoring was complex and difficult 
to apply across their entire sample size.35 A tiered management protocol guided by PbtO2 
and ICP monitoring was largely successful in BOOST-II; although they admit that 
treatment aimed at improving cerebral oxygenation had a small risk of significant adverse 
events, specifically respiratory events (4%), which may have confounded 6-month 
outcome measures.25 In conclusion, the RCT design allows for implementation of 
specific interventions, treatment guidelines, elimination of physician bias, and minimizes 
the effects of inter-subject variability, and is a logical choice for our proposed study.  
2.5.2 Study Design 
 As previously discussed, authors collectively agree that a large prospective RCT 
is necessary to establish the significance and clinical efficacy of a multimodal monitoring 
approach in TBI. Successive editions of the Guidelines for the Management of Severe 
Traumatic Brain Injury have noted that data from RCTs that have been conducted is 
lacking, and only a few high quality prospective cohort studies exist.10 In our proposed 
two-arm single blind prospective, multicenter RCT, we will be able to control for 
confounding, reduce physician bias, and obtain high quality evidence to establish a 
relationship between a treatment protocol informed by cerebral oxygenation monitoring 
by NIRS and its effect on BTH and functional outcome. 
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2.5.3 Study Population and Selection Criteria   
 In accordance with the Guidelines for the Management of Severe Traumatic Brain 
Injury, observational studies, and adaptations from RCTs by Okonkwo, et al. and 
Chesnut, et al., the population selected will meet certain characteristics.10,15-17,23,25 
Patients will be 18 or older with severe TBI and meet clinical need for ICP monitoring. 
Selection will come from three academic, tertiary care, level I Trauma centers in the state 
of Connecticut with the appropriate resources to monitor and treat to the specifications of 
our protocol. Inclusion of three of the largest and most diverse medical centers in the 
state will allow for appropriate external validity. Like other studies in review, inclusion 
criteria will consist of severe TBI as defined by admission GCS and baseline 
demographic characteristics. Exclusion criteria will be similar to conditions established 
by previously reviewed studies, and include penetrating injury, GCS out of specified 
range, pregnancy, and age out of specified range, among others. Specific inclusion and 
exclusion criteria will be discussed in detail in Chapter 3.  
2.5.4 Selection of Variables   
 Our proposed intervention will be cerebral oxygenation monitoring by NIRS plus 
ICP monitoring for 72 hours to guide a specified treatment regimen to determine efficacy 
of reducing burden of BTH and improving 6-month functional outcomes. Monitors will 
be placed within 12 hours of admission after confirming eligibility criteria based on 
inclusion and exclusion guidelines and consent agreement. Our proposed study design, 
timing and duration of monitor placement is comparative to previous RCTs that had 
analyzed the relationship of multimodal monitoring in TBI.17,25 Although the trial by 
Chesnut, et al. found no significant improvement in functional outcomes with ICP 
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monitoring, its inability to refute its efficacy and the inclusion of ICP monitoring in the 
current guidelines is the primary factor for inclusion in our study as our control.10,17 
Additionally, safety and feasibility of regional brain tissue oxygen (PbtO2) monitoring 
was supported in BOOST-II, but was underpowered to show clinical significance, though 
there was a trend towards improved outcomes.25 Well-documented limitations in PbtO2 
monitoring, insufficient data, and promise for noninvasive strategies such as NIRS 
cerebral oxygenation monitoring is the primary determinant for including NIRS 
monitoring in our intervention arm instead of PbtO2.12,25,35  
2.5.5 Treatment Protocol 
 The primary variable in our study design is the monitoring modality that each 
patient is randomized to; either NIRS plus ICP monitoring, or ICP monitoring alone, and 
how that approach influences treatment. Based on those physiological parameters and the 
treatment they guide, we will determine the efficacy of cerebral oxygenation monitoring 
by NIRS and ICP monitoring in reducing BTH and improving long-term functional 
outcome. A stepwise management protocol will be standardized across our study and 
adapted from the Guidelines for the Management of Severe Traumatic Brain Injury and 
BOOST-II.10,25 A protocol based on ICP values and cerebral oxygenation values by 
PbtO2 was safely and feasibly implemented in BOOST-II.25 We will use a similar 
protocol and adapt its thresholds based on NIRS criteria for BTH, instead of PbtO2, 
which will be described in greater detail in Chapter 3.  
2.5.6 Primary and Secondary Outcomes 
 Our primary outcome is to determine if treatment guided by cerebral oxygenation 
monitoring with NIRS in addition to ICP monitoring can reduce the burden of BTH over 
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72 hours as compared to ICP monitoring alone. As previously discussed, BTH is a 
common cause of secondary brain injury after severe TBI and its extent, duration and 
depth is associated with negative outcomes in this population.22,24-26 BTH has been 
analyzed as an outcome measure in a number of previously reviewed studies, and 
therefore it is reasonable to propose that median duration of BTH over both arms will be 
the primary measurement by which efficacy of both the intervention and control groups is 
determined in our study.23,25,35  
 Our secondary outcome is to determine the functional outcome in each of our 
groups at 6 months post initial injury utilizing the GOS-E 8-point rating system. Almost 
all of the studies reviewed utilize some measurement of outcome, whether it be in-
hospital mortality,13-16,30 overall mortality,17,31,35 GOS,23,31 or GOS-E.17,25 GOS-E is an 
expanded 8-point ordinal outcome scale and provides increased sensitivity relative to the 
original 4-point GOS that was used in earlier studies. Using GOS-E allows for 
classification of a wider range of functional outcomes including death, and corresponds 
to a necessary sample size reduction on the order of 3-5%.41 Additional outcomes will 
include number of interventions taken in each group, and incidence of serious adverse 
events throughout the entire study period.  
2.5.7 Conclusion 
 The existing evidence supports the promise of cerebral oxygenation monitoring in 
guiding treatment regimens to lower BTH and improve functional outcomes in severe 
TBI. Clarifying its use in clinical practice alongside the current accepted standard of 
multimodal monitoring is essential to inform its efficacy and utility in treatment of this 
population. Exploring the possibility of monitoring cerebral oxygenation in a noninvasive 
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manner through NIRS is an exciting advancement in the field that has been shown to 
have preliminary success and is a logical choice for further investigation. Authors 
recognize that there are still inconsistent outcome measures, confounding, and 
inconclusive data regarding the utility and use of certain monitoring modalities in TBI 
care. Our proposed multicenter RCT will allow for control of confounding factors, a 
standardized outcome measure consistent with recent literature, and determination of 
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Chapter 3: Study Methods 
3.1 Study Design 
 We will conduct a two-arm single blind prospective, multi-center RCT among 
adult hospitalized patients with severe TBI. We will compare the median time of BTH in 
TBI with patients being managed with a treatment protocol informed by ICP monitoring 
alone (control) against one informed by ICP monitoring plus cerebral oxygenation 
monitoring with NIRS (intervention). 
3.2 Study Population and Sampling 
 Our source population will be derived from inpatient adults aged 18 and older 
with severe TBI and clinical need for ICP monitoring according to the Guidelines for the 
Management of Severe Traumatic Brain Injury, 4th Edition.1 Eligible medical facilities 
include three academic, tertiary care, Level 1 trauma centers in the state of Connecticut: 
Yale New Haven Hospital, St. Francis Hospital and Hartford Hospital.  
 Inclusion criteria will consist of the following: male and female patients aged 18 
and older admitted to eligible medical centers with severe TBI, not following commands 
after resuscitation and without influence of paralytics or sedation, clinical need for ICP 
monitoring according to the Guidelines for the Management of Severe TBI, 4th edition, 
and ICP monitor placement within 12 hours of presentation.  
 Exclusion criteria will include: penetrating brain injury, neurological exam 
suggestive of imminent brain death, uncertain neurologic exam, pregnancy, chest/lung 
injury evident on diagnostic imaging likely to produce hypoxia independent of brain 
injury, and inability to obtain authorized consent from subject or from legal authorized 
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representative (LAR). Presence of intracranial hematomas will not be excluded, and will 
be reported in participant baseline characteristics (Table 3).  
3.3 Subject Protection and Confidentiality 
 This study will be reviewed by the Institutional Review Board (IRB), a 
commission of Yale University’s Human Research Protection Program, in accordance 
with IRB Policy 100 PR.1. Based on the functional and cognitive status of our study 
population, we will act in accordance to IRB Policy 340: Participation of Individuals with 
Impaired Consent Capacity, which will employ additional safeguards in order to protect 
our participant’s rights and welfare, including appropriateness and justification of 
inclusion, risk/benefit assessment, and the use of a surrogate or LAR for decision making 
on each subject’s behalf. We will require written, informed consent (Appendix B) from 
each LAR before inclusion, which will outline the purpose of the research, study design 
and procedures, expected duration, risks, and potential scientific and personal benefit of 
their participation. In addition, the consent form will outline that each LAR has the right 
to withdraw from the study at any time if he/she feels unsatisfied with treatment. 
Continued participation consent will be obtained at or before the 6-month follow-up visit 
by LAR or participant if they regain cognitive capacity. All clinical information in this 
study will be kept confidential and research will be conducted in accordance to the Health 
Insurance Portability and Accountability Act (HIPAA). Additionally, all clinical and/or 
research staff involved in care of participants will be required to undergo HIPAA training 
prior to initiation of this study if they have not already done so.   
3.4 Recruitment 
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 Any patient over the age of 18 who presents to the emergency department of 
participating locations with mechanism of injury consistent with head trauma will be 
evaluated in conjunction with the trauma surgery/ neurocritical care team for inclusion 
criteria. Once a thorough trauma assessment has been completed, the patient is 
hemodynamically stable and diagnostic imaging is complete, they will be evaluated for 
inclusion criteria. If the patient is deemed a viable candidate, an LAR will be identified 
and given information and consent to enroll in the study. Since this protocol is time 
sensitive, it is imperative that an LAR is identified in a timely fashion, and that study 
guidelines, eligibility, and medical and scientific benefits of their enrollment are 
discussed before agreement.  
3.5 Study Variables and Measures 
 The intervention group will include patients managed by a protocol determined by 
ICP and cerebral oxygenation monitoring with NIRS, while the control group will be 
patients managed by a protocol determined by ICP monitoring alone. Intraparenchymal 
ICP monitors and noninvasive NIRS monitors will be placed within 12 hours in each 
patient before they are subsequently randomized.  In the intervention group, 
measurements of ICP, SctO2 (as measured by NIRS) and CPP will be monitored at 5-
minute intervals, and treatment will be initiated in a stepwise fashion based on specific 
physiological thresholds. In the control group, the same protocol will be in place, but 
providers will be blinded to SctO2 and instructed to manage based on ICP and CPP 
alone.  
 The primary outcome will be to determine if treatment guided by cerebral 
oxygenation monitoring with NIRS plus ICP monitoring can reduce the burden of BTH 
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over a 72-hour period as compared to ICP monitoring alone. The secondary outcome will 
be functional outcome as defined by GOS-E at 6 months post initial injury, evaluated by 
a trained member of our research team who was blinded to the intervention group.2 An 
additional secondary outcome will be number of interventions taken in each group.  
3.5.1 Treatment Algorithm and Thresholds 
 Treatment protocols and thresholds will be adapted from the current Guidelines 
for the Management of Severe Traumatic Brain Injury, 4th Edition, as well as BOOST-II. 
Treatment protocol is directed at a set combination of physiological interventions that 
will address elevated ICP alone, or BTH and elevated ICP in conjunction. Our control 
and intervention groups will be managed based on specific thresholds for intervention, 
which include: ICP ≥ 22 mmHg; CPP ≤ 60 and ≥80 mmHg; unintentional hyperthermia 
or hypothermia; blood glucose <60 or >150 mg/dL; and standard hospital protocol 
involving correction of electrolyte abnormalities. The intervention group will be managed 
with the addition of a physiological threshold of BTH, defined as: SctO2 (as measured by 
NIRS) ≤ 50%. With utilization of medical management defined by these thresholds, the 
median duration of BTH over a 72-hour period will be determined among each group.  
 After initial stabilization, standard management will include early identification 
and evacuation of all traumatic hematomas and intubation and ventilation with goal of 
SaO2 > 93% and PaCO2 30-40 mmHg. Increase in PaCO2 is associated with an increase 
in cerebral blood flow, which in turn provides increased oxygenation to brain tissue, but 
may increase total brain volume and ICP as well.1 Subsequent treatment protocols will be 
grouped based on which physiologic threshold is breached. The control group will trigger 
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intervention only with evidence of ICH, while our intervention group will trigger 
intervention if either variable is out of range.  
1) Group A: ICP < 22mmHg, SctO2 > 50%, no treatment required. 
2) Group B: ICP ≥ 22, SctO2 > 50%, will require treatment in both control and 
intervention group based on the presence of elevated ICP.  
3) Group C: ICP < 22mmHg, SctO2 ≤ 50%, will require treatment from the intervention 
group based on BTH, but will not require treatment in the control group based on ICP 
within defined range. 
4) Group D: ICP ≥ 22, SctO2 ≤ 50%, will require treatment from both the control and 
intervention groups, based on the presence of elevated ICP and BTH. 
 Brief physiologic elevations in ICP or reductions in SctO2 may occur throughout 
the 72-hour monitoring period, so our threshold to intervene will occur at 10 minutes (or 
two consecutive readings, measured 5 minutes apart) of continuous elevated ICP or BTH 
as defined by our values above.  The following protocol will outline the specific 
interventions that will be taken to correct the variance in either ICP or SctO2, and will be 
taken in a stepwise approach as listed. If at any point during the protocol physiological 
variables return to normal range, clinicians should discontinue further intervention. 
Group B Intervention: (1) elevate head of bed, (2) ensure sufficient sedation of the 
patient with propofol at 0.3 mg/kg/hour, titrating by 5 to 10 mcg/kg/minute every 5 to 10 
minutes until proper sedation is achieved,3 (3) ensure T <38° C, control with IV 
acetaminophen as needed, as fever increases metabolic demand and can increase ICP 
with elevated CBF, (4) transfuse 1 U pRBCs until Hgb ≥ 7 mg/dL, (5) hypertonic saline 
250 mL IV bolus titrated to control ICP, while maintaining serum Na+ 155-160 mEq/L, 
 45 
(6) IV Mannitol 1g/kg 20% solution, with repeat dosing every 6-8 hours as needed at 
0.25-1 g/kg and maintaining systolic BP > 90 mmHg, (7) therapeutically adjust 
ventilatory rate to lower PaCO2 to 32-35 mmHg. If refractory, (8) repeat CT Head non-
contrast to evaluate for bleeding or mass effect, then (9) consider removal of CSF at 1-2 
mL/min with external ventricular drain (EVD) into the lateral ventricle on least affected 
side, (10) pentobarbital bolus at 5-20 mg/kg, titrated at 1-4 mg/kg/hour to achieve 
induced coma, and finally (11) decompressive craniectomy. 
Group C Intervention: (1) elevate head of bed, (2) ensure T <38° C, control with IV 
acetaminophen as needed, (3) transfuse 1 U pRBCs until Hgb ≥ 7 mg/dL, (4) increase 
PaO2 by adjusting ventilator parameters to increase FiO2 to 60% initially, increase until 
100% as needed based on response, (5) increase PaO2 by increasing Positive End 
Expiratory Pressure (PEEP) accordingly, (6) therapeutic hyperventilation to increase 
PaCO2 to 45-50 mmHg, (7) transfuse pRBC to goal Hgb > 10 g/dL. 
Group D Intervention: (1) elevate head of bed, (2) ensure T <38° C, control with IV 
acetaminophen as needed, (3) pharmacologic sedation as listed in Group B protocol 
above, titrated to effect, (4) transfuse pRBCs until Hgb ≥ 7 mg/dL, (5) hypertonic saline 
250 mL IV bolus titrated to control ICP, while maintaining serum Na+ 155-160 mEq/L, 
(6) IV Mannitol 1g/kg 20% solution, with repeat dosing every 6-8 hours as needed at 
0.25-1 g/kg and maintaining systolic BP > 90 mmHg, (7) obtain arterial blood gas to 
determine if oxygenation is within desired range, if not, increase FiO2 by increasing 
PEEP accordingly (increase to 60% and up to 100% as needed based on response), (8) 
remove CSF at 1-2 mL/min with EVD as listed in Group B protocol. If treatments are 
refractory, consider (9) high dose IV Mannitol >1 g/kg 20% solution, (10) transfuse 
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pRBCs until Hgb ≥ 10 mg/dL, (11) attempt to increase CPP >70 mmHg with IV normal 
saline fluid boluses, (12) repeat CT Head non-contrast to evaluate for bleeding or mass 
effect and then (13) treat surgically correctable lesions with craniotomy, (14) induced 
hypothermia to 35-37° C using active cooling measures, (15) pentobarbital bolus at 5-20 
mg/kg, titrated at 1-4 mg/kg/hour to achieve induced coma, (16) induced hypothermia to 
32-34.5° C, and finally (17) decompressive craniectomy.  
3.6 Assignment of Intervention and Blinding 
 Participants who meet inclusion criteria will be randomly allocated by computer 
generation to either intervention or control group in a matched, one to one ratio until 
sample size in each arm is achieved. To reduce the likelihood of an imbalance of clinical 
severity factors between groups, a covariate-adjusted randomization scheme will be used 
in this study.4  The goal of randomization is to create groups that are comparable with 
respect to prognosis and clinical site and without selection bias. Therefore, adjustment 
variables will include two factors: clinical site, and probability of a poor outcome as 
defined by the IMPACT core model. Matching based on prognosis will occur by 
separating subjects into three distinct categories as determined by IMPACT core model 
scores and distributed evenly among both control and intervention groups. Categories 
will be defined as: (a) IMPACT score 0-5, (b) IMPACT score 6-10, or (c) IMPACT score 
11-15. Subjects will then be evenly distributed among these three categories and the three 
included clinical sites. This scheme will be utilized to prevent an imbalance of participant 
inclusion from any one particular site, and clinical severity imbalances among groups. 
Otherwise, as long as participants meet inclusion criteria no preference to either group 
will be given based on mechanism of injury, comorbidities, gender, or physician 
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determined prognosis of outcome. Therefore, nonbiased representation of each group will 
be maintained throughout our study. 
 Researchers involved in our study including those collecting data, any 
nonessential healthcare providers, and researchers evaluating GOS-E will be blinded to 
allocation group.  Based on the nature of our study design, it is impossible to blind 
individual healthcare providers responsible for implementing treatment protocols once 
each monitor is in place. However, treatment protocols have been controlled for, which 
will eliminate physician biases and limit potential confounding. Additionally, LAR’s and 
family members will be blinded to group assignment and treatment protocol, as will be 
outlined in their consent agreement.  
Table 3. Participant Baseline Characteristics  
Characteristic Control Intervention P-Value 
Subjects (n)    
Average Age    
Male Gender (%)    
Race (%) - - - 
- White    
- Black    
- Hispanic    
- Other    
Average GCS (3-15)    
Average Motor Score (0-6)     
Average IMPACT score (0-15)    
Evidence of Hematoma on CT (%)    
- Epidural Hematoma (%)    
- Subdural Hematoma (%)    
- Subarachnoid Hemorrhage (%)    
 
3.7 Adherence and Monitoring of Adverse Outcomes 
 In order to reduce drop out rates after our initial outcome is assessed, recruiters 
from the research study will be contacting subjects and LAR’s once a month via 
telephone or electronic mail in order to maintain communication before their scheduled 
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6-month follow-up.  They will be contacted again one week before their scheduled 
follow-up appointment to ensure their participation and coordinate logistics of their 
appointment. Participants will be reimbursed for any travel expenses pertaining to in-
person follow-up at their 6-month appointment. 
 During communication, participants will be asked to provide information on 
serious adverse events (SAE), which will be defined in our study as any medical 
occurrence that results in death, is life-threatening, requires inpatient hospitalization or 
prolongation of existing hospitalization, or results in persistent or significant disability or 
incapacity.5  
3.8 Data Collection 
 Once an LAR has signed consent and the subject is hemodynamically stable, an 
ICP monitor will be inserted 1.5-2 cm into brain parenchyma through a burr hole, with 
positioning close to, but not directly in the area most at risk. Subjects will then undergo a 
non-contrast CT Head to evaluate for proper placement of each monitor. CASMED-
Foresight NIRS monitors will subsequently be placed and each respective modality will 
record ICP and SctO2 continuously. These values will be transmitted at 5-minute 
intervals over the 72-hour span and sent to a private laptop for data compilation that will 
be analyzed at the completion of each individual trial. Attending clinical staff will also be 
responsible for routine monitoring and charting of significant events, repositioning, vital 
signs, routine lab work, ventilator settings and arterial blood gas values when available 
(pH, PaCO2, and PaO2).  
 As described in section 3.7, research staff will maintain communication with 
subjects and LARs at specified intervals after the initial 72-hour monitoring period is 
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complete. Six months after initial presentation each subject will be evaluated by a trained 
researcher for functional status as outlined by GOS-E. Evaluation will be done at a 
private site in New Haven, CT by a single evaluator, and coordination of logistics will be 
done previously to ensure each subjects attendance. If a subject is in the hospital or 
rehabilitation facility at the time of their session and is not safe to leave, additional 
measures will be taken so that the evaluator can conduct the evaluation at their current 
location. Each session will consist of a standardized interview and physical exam focused 
on each subject’s ability to carry out activities of daily living. A more detailed description 
of the assessment is included in Appendix A. 
3.9 Sample Size Calculation 
 Sample size was calculated to detect a difference in median duration of BTH over 
72 hours of continuous monitoring. Sample size was based on an adaptation of BOOST-
II, an RCT that analyzed a similar outcome and population. Using this study, calculation 
was made using sample size statistics in Power and Precision 4. For a given effect size 
(population means of 0.440 vs 0.150), SD (0.310), sample sizes of 36 and 36, and alpha 
(0.010, 2 tailed), power is 0.903. This means that 90% of studies would be expected to 
yield a significant effect, rejecting the null hypothesis that the two-population means are 
equal. In order to properly power our study to compare medians, we will add a 15% 
correction (10 or more patients) to account for comparison of medians and correction for 
losses to follow up. Therefore, in order to achieve an alpha of 0.050 and maintain power, 
we estimate that we will need a sample size of 50 subjects in each study group, with a 
final sample size of 100 patients. The sample size calculation will be included in 
Appendix C. 
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Table 4. Prevalence of BTH, ICH, or low CPP over 72-hour duration of trial 
 
Variable Measurement of Variable  
Subjects with BTH (SctO2 <50%), (n)  
-Median Duration of BTH, (t)  
Subjects with ICH (ICP ≥ 22), (n)  
-Median duration of ICH, (t)  
Subjects with reduced CPP (<60 mmHg)  
- Median duration of reduced CPP, (t)   
 
Table 5. Glasgow Outcome Scale- Extended (GOS-E), evaluated at 6 months 
Score Interpretation 
1= Dead Dead 
2= Vegetative State Absence of awareness of self and environment 
3= Lower Severe Disability  Needs full assistance in ADLs 
4= Upper Severe Disability  Needs partial assistance in ADLs 
5= Lower Moderate 
Disability 
Independent, but cannot resume work/school or all 
previous social activities  
6= Upper Moderate 
Disability  
Some disability exists, but can partly resume work or 
previous activities  
7= Lower Good Recovery  Minor physical or mental deficits that affect daily life 
8= Upper Good Recovery  Full recovery or minor deficits that do not affect daily life 
 
Table 6. Number of interventions required in each group throughout 72-hour period 
 
Assignment Group and Type of 
Intervention 
Number of Interventions (total, 
average per subject in group) 
Control  - 
- Group B protocol  
- Group D protocol  
Intervention  - 
- Group B protocol  
- Group C protocol  
- Group D protocol  
 
3.10 Analysis  
 Statistical analysis will occur with an intention-to-treat principle and be 
performed using Mann-Whitney U for nonparametric variables for both our primary and 
secondary outcomes. This statistical analysis is supported by previously reviewed studies 
that have analyzed similar associations. Primary outcome will be to determine if 
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treatment guided by cerebral oxygenation monitoring with NIRS in addition to ICP 
monitoring can reduce the median duration of BTH burden over 72 hours as compared to 
ICP monitoring alone. SctO2 values will be recorded continuously and logged every 5 
minutes in order to obtain cerebral oxygenation data over a 72-hour span.  
 Our secondary outcome will be to determine functional outcome of each subject 
in each of our groups at 6 months post initial injury utilizing the GOS-E on an 8-point 
rating system. Each subject will receive a score by a trained researcher who will be 
blinded to group allocation and interventions taken throughout the study. Additional 
outcomes that will be evaluated include frequency and type of interventions by 
assignment group and occurrence and type of SAE. 
3.11 Timeline and Resources 
 Our study will be performed over a two-year time period beginning on July 1, 
2020. This time frame includes recruitment and training of clinical staff, patient 
enrollment and data collection, and outpatient follow-up. Anticipated timeline consists of: 
recruitment and training of appropriate clinical staff across three locations (months 0-2); 
phase 1 (and phase 2 dependent on timing of subject recruitment) of study protocol with 
rolling recruitment until sample size is reached (months 2-18); completion of phase 2 of 
study protocol (months 18-24). Phase 1 refers to the initial study protocol including 
inpatient management and 72-hour monitoring and treatment period, while phase 2 refers 
to the time period after 72 hours and the 6-month follow up visit. The last subject must be 
enrolled no later than month 18 to ensure that each subject has a full 6 months before 
follow up. Statistical analysis will occur immediately after the 6-month follow-up 
appointments are completed following month 24 and are anticipated to take 1-2 months.  
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Study protocol will be initiated immediately after each subject is hemodynamically stable 
and consent is obtained from an LAR and will be complete after a total of 6 months and 3 
days. Sufficient supply of monitors, ventilators and support equipment at each location 
must be confirmed before any subject is enrolled. An outpatient exam site will be 
confirmed in New Haven, CT for 6-month follow-up appointments provided by the Yale 
New Haven Hospital Department of Neurology.  
 Study personnel at each site will include: one attending physician, two advanced 
practice practitioners (physician assistants or nurse practitioners) and four nurses among 
both trauma and intensive care units that will be recruited and trained in our study 
protocol to ensure 24-hour coverage. Additionally, a research assistant for data collection, 
a statistician and a GOS-E evaluator will be trained in pertinent aspects of our study.   
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Chapter 4: Conclusion 
 
4.1 Study Advantages 
 The major advantages of our proposed study lie primarily in its design, 
methodology, and specific predetermined evidence-based treatment protocol.1,2 To date 
there have been no large, prospective clinical trials examining noninvasive monitoring in 
severe TBI, and no RCTs specifically analyzing cerebral NIRS as a monitoring technique 
in adults within this population. Our proposed multicenter RCT aims to determine 
whether cerebral oxygenation monitoring with NIRS can reduce the burden of BTH and 
be incorporated into a standardized multimodal monitoring approach to guiding treatment 
of severe TBI.  
 Most relevant studies on this matter are observational in nature, are subject to 
physician biases,3-6 and contain a high prevalence of confounding factors. By matching 
control and intervention groups among clinical sites and IMPACT prognostic scoring, our 
study will drastically reduce the potential for confounding. Additionally, providing 
proper training for clinical staff and implementing a fixed treatment protocol triggered by 
specific, predetermined physiological variables will limit variability in treatment among 
patients across multiple clinical locations. These measures will serve to increase our 
study’s internal validity and reduce clinician biases.  
 Previous studies have been significantly limited by sample size, however with 
utilization of three large, Level I trauma centers in CT over a 16-month period we will 
ensure enrollment of an adequate sample size that will be generalizable to a larger 
population. Our study has feasibly proposed a high quality, evidence-based protocol that 
can potentially influence current guidelines and determine whether cerebral oxygenation 
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monitoring with NIRS is a justified addition to the current guidelines for multimodal 
monitoring of TBI.  
4.2 Study Disadvantages 
 One major disadvantage of our study is the variability of injury. Although each 
subject will be enrolled based on satisfaction of inclusion criteria, each mechanism of 
injury, subsequent brain trauma, intracranial bleeding, and other sequelae of traumatic 
injury are inherently different and cannot reasonably be controlled for based on our ideal 
sample size and time restrictions. Importantly, significant scalp swelling and the presence 
of intracranial hematomas can contaminate the NIRS signal and lead to inconsistent 
measurements, and cannot be controlled for based on the nature of our population.7  
 Similar to a 2015 RCT by Hyttel-Sorensen, et al., a significant disadvantage of 
our study design is that blinding of group allocation to trained clinical staff is 
impossible.8 To execute the treatment protocol as designed, clinicians must know to treat 
based on group allocation, and therefore cannot be blinded. However, since each protocol 
is predetermined and physician bias is minimal, this should not have a significant effect 
on our results. Additionally, in many cases the responsibility to maintain communication 
with researchers and coordinate 6-month follow-up visits is dependent on each subject’s 
LAR. This introduces burden to these representatives who are not directly participating in 
the study and may potentially increase loss to follow-up or have a negative effect on 
maintaining communication with each subject during the follow-up period. 
4.3 Clinical and Public Health Significance  
 TBI is a leading cause of death and disability in the United States, accounting for 
prolonged hospital admissions, financial stressors, and long-term reductions in functional 
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status and quality of life. Current guidelines are focused on monitoring and treating 
physiological variations in ICP and CPP in order to prevent secondary brain injury, but 
there is a lack of level I prospective clinical evidence proving their efficacy. Cerebral 
oxygenation monitoring with and without NIRS has also been examined in recent 
literature as an addition to a multimodal monitoring strategy in managing these patients, 
but research is inconclusive and techniques are imperfect. Considering the prevalence of 
TBI and its potentially devastating effects, there is a clinical need for consensus on 
monitoring techniques in management of these patients.   
 By proposing a prospective, multicenter RCT we aim to determine if cerebral 
oxygenation with NIRS is a suitable technique to reliably monitor cerebral oxygenation 
and reduce BTH in severe TBI patients. Its efficacy in this trial will potentially determine 
if it is a safe, noninvasive alternative to invasive cerebral oxygenation monitoring, and if 
it is of benefit in guiding management in our target population. Ultimately, our study will 
help to clarify the current guidelines for monitoring and managing patients with severe 
TBI and determine whether cerebral oxygenation monitoring with NIRS is suitable for 
inclusion into a multimodal management approach for these patients. 
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Appendix A. Glasgow Outcome Scale- Extended (GOS-E) 
 
Score Interpretation 
1= Dead Dead 
2= Vegetative State Absence of awareness of self and environment 
3= Lower Severe Disability  Needs full assistance in ADLs 
4= Upper Severe Disability  Needs partial assistance in ADLs 
5= Lower Moderate Disability Independent, but cannot resume work/school or all 
previous social activities  
6= Upper Moderate Disability  Some disability exists, but can partly resume work or 
previous activities  
7= Lower Good Recovery  Minor physical or mental deficits that affect daily life 
8= Upper Good Recovery  Full recovery or minor deficits that do not affect daily 
life 
 
Consisting of: (1) Detailed client interview (2) Collateral interviews (in person or 
questionnaires) (3) Functional Testing (4) Synthesis of Data 
 
Expanded Description of Categories:  
8 levels are in the scale: Minimum score = 1, maximum score = 8 
 
Level 1: Dead 
 
Level 2: Vegetative State- condition of unawareness with only reflex responses but with 
periods of spontaneous eye opening  
 
Level 3 and 4: Lower and Upper Severe Disability – Patient who is dependent for daily 
support for mental or physical disability, or usually a combination of both. If the patient 
can be left alone for more than 8 hours at home, it is upper level of severe disability (4). 
If patient cannot be left at home for more than 8 hours, it is considered lower level of 
severe disability (3) 
 
Level 5 and 6: Low and Moderate Disability- patients have some disability such as 
aphasia, hemiparesis or epilepsy and/or deficits of memory or personality but are able to 
care for themselves. They are independent at home but dependent outside. If they are able 
to return to work with or without special arrangement, they are categorized as upper 
moderate disability (6). If they are unable to return to work, they are categorized as lower 
moderate disability (5).  
 
Level 7 and 8: Lower and Upper Good Recovery- Resumption of normal life with the 
capacity to work even if pre-injury status has not been achieved. Some patients have 
minor neurological or psychological deficits. If these deficits are not disabling, then they 
are categorized as upper good recovery (8). If these deficits are disabling, they are 
categorized as lower good recovery (7).  
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Appendix B. Sample HIC Consent Form 
Created using 200 FR.7 HIC Consent For Participation in a Research Project Template 
 
CONSENT FOR PARTICIPATION IN A RESEARCH PROJECT 
 
200 FR. 7 (2016-1) 
YALE UNIVERSITY SCHOOL OF MEDICINE – YALE-NEW HAVEN 
HOSPITAL 
HARTFORD HEALTHCARE- HARTFORD HOSPITAL 
TRINITY HEALTHCARE- ST. FRANCIS HOSPITAL AND MEDICAL CENTER 
 
Study Title: Cerebral Oxygenation Monitoring by Near-Infrared Spectroscopy in Severe 
Traumatic Brain Injury  
Principal Investigator: Emily J. Gilmore, MD 
Co-Principal Investigator: Drew H. Zimmerman, PA-SII 
Funding Source: The Brain Trauma Foundation  
 
Invitation to Participate and Brief Description of the Project 
You or the person you legally represent are invited to participate in a research study 
called Cerebral Oxygenation Monitoring by Near Infrared Spectroscopy in Severe 
Traumatic Brain Injury. This form is addressed to the person who will enroll in the study 
but should also be reviewed by a legally authorized representative for consent if 
applicable. This study is designed to determine the efficacy of a new monitoring 
technique employed in patients with severe traumatic brain injury that will help guide 
treatment and potentially improve functional outcomes. You have been invited to 
participate because you have been diagnosed with a severe traumatic brain injury and 
meet our study’s inclusion criteria. About 100 persons will be asked to participate in the 
study over a 2-year time period. 
 
In order to decide whether or not you wish to be a part of this research study you should 
know enough about its risks and benefits to make an informed decision. This consent 
form gives you detailed information about the research study, which a member of the 
research team will discuss with you. This discussion should go over all aspects of this 
research: its purpose, the procedures that will be performed, any risks of the procedures, 
possible benefits and possible alternative treatments. Once you understand the study, you 
will be asked if you wish to participate; if so, you will be asked to sign this form. 
 
Description of Procedures  
If you agree to participate in this study, you will be randomly assigned to one of 
two treatment groups: (a) control group that will monitor you based on current guidelines, 
and, (b) an experimental group that will monitor you based on current guidelines plus a 
noninvasive measurement tool to assess your brain’s oxygen status. If placed in our 
control group, you will be monitored and then treated with a predetermined protocol 
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designed according to the current Guidelines for Management of Severe Traumatic Brain 
Injury, 4th Edition, if warranted. In our experimental group, the same procedures will 
apply, with addition of an extra monitoring strategy that will help guide a treatment 
protocol with additional steps based on those values.  
 
 At the time of reading this consent, you have been brought to one of three 
participating facilities included in this study (Yale-New Haven Hospital, Hartford 
Hospital, or St. Francis Hospital) for evaluation of a traumatic head injury. Your injury 
has been categorized as severe by our clinical staff and based on current guidelines you 
meet clinical criteria for intracranial pressure monitoring.  
 
 Regardless of which group you are randomized to, you will undergo a procedure 
that involves placing an intracranial pressure monitor, which is the standard of care for 
managing patients with severe traumatic brain injury. We will sedate you with general 
anesthesia and place a probe through a small hole into the skull. To insert the probe a 
small cut is made in the scalp and a hole is drilled into the skull beneath the cut. The 
probe is placed 1.5-2cm into the brain tissue and positioned close to, but not directly in, 
the area injured.  The probe is connected to an electronic measuring device that monitors 
the brain pressure. You will then undergo a computed tomography (CT) scan to ensure 
proper placement of the monitor. The cut will be closed with sutures or staples after the 
trial and once it is no longer needed. You will not be aware of this procedure once under 
sedation and will not experience any pain or physical sensation. You will be intubated 
and placed on a ventilator before proceeding.  
 
 If you are randomly selected to participate in our experimental group, near 
infrared spectroscopy detectors will be placed on your skull for additional monitoring of 
your brain tissue oxygen levels. These detectors are stickers that are noninvasive and 
require no surgical intervention. They will have multiple wires attached to them that will 
transmit the information to our monitor for reading. If you are in our control group the 
same monitors will be placed, but clinical staff will be instructed not to use information 
from the near infrared spectroscopy detectors in determining your care. Throughout the 
study, you and your family will not be aware of which group you have been selected to. 
 
 All monitors will be placed within 12 hours of your initial presentation to the 
hospital, and once in place, information from them will be recorded for 72 hours. Over 
that time period, a predetermined, evidence-based treatment protocol will be 
implemented for any monitored value that is out of range. Treatment protocols are 
dependent on which group you will be randomized to but will be consistent among all 
participants in the study. After the 72-hour study period is complete, near infrared 
spectroscopy monitors will be removed, and your treatment and subsequent hospital 
course will be directed by individual hospital protocol. 
 
 After the 72-hour period is complete, investigators will contact you and/or your 
LAR at scheduled intervals each month via e-email or phone call. During these periods of 
communication, you will be asked to provide information on any location changes or 
moves, hospital discharge or readmission, significant adverse events, or death. If you 
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remain admitted or are readmitted to any of our participating hospitals, we will monitor 
your electronic medical record for updates.  
  
 6 months after your hospital admission you will be asked to be present for a 
follow up appointment with one of our researchers at our clinic in New Haven, 
Connecticut. One week before this meeting, an investigator will contact you and review 
logistics of travel and will reimburse you for any costs accrued while traveling to your 
appointment. At this appointment, you will be asked a series of questions that will 
indicate your functional ability to work and carry out activities of daily living, and then 
will undergo a physical exam.  
 
 A description of this study is available on http://www.ClinicalTrials.gov, as 
required by U.S. Law. This Web site will not include information that can identify you. 
The purpose of this database is to allow everyone to see information on what studies are 
being done, and what studies have been done. At most, the Web site will include a 
summary of the results. You can search this Web site at any time. 
 
Risks and Inconveniences 
 
(1) Intracranial Pressure Monitoring: There are risks and complications with this 
procedure. They include but are not limited to the following: 
➢ Common risks and complications (more than 5%) include: minor pain, 
bruising and/or infection from IV cannula site. This may require treatment 
with antibiotics.  
➢ Uncommon risks and complications (1-5%) include:  
➢ Infection, requiring antibiotics and further treatment.  
➢ Bleeding can occur and may require a return to the operating room. Bleeding 
is more common if you have been taking blood-thinning drugs such as 
Warfarin, Aspirin, Clopidogrel (Plavix) or Dipyridamole. 
➢ Heart attack due to the strain on the heart. 
➢ Stroke or stroke like complications may occur causing neurological deficits 
such as weakness in the face, arms and legs. This could be temporary or 
permanent.  
➢ Fluid leakage from around the brain may occur through the wound after the 
operation. This may require further surgery.  
➢ Inadequate placement or malfunction of the probe and/or device. This may 
require further surgery. 
➢ Blood clot in the leg (DVT) causing pain and swelling. In rare cases part of 
the clot may break off and go to the lungs.  
➢ Rare risks and complications (less than 1%) include: 
➢ Seizure which may require medication 
➢ Injury to the brain, important nerves or blood vessels. This can lead to stroke 
like complications.  
➢ Death as a result of this procedure is very rare. 
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(2) Near Infrared Spectroscopy Monitoring: There are minimal to no risks involved in 
this monitoring technique. There is no need for injection of any medication, IV access or 
surgical intervention. Areas of hair may need to be shaved in order to place the detectors 
in proper position.  
 
(3) Treatment Protocols: There are potential risks associated with each specific 
intervention outlined in our treatment protocol. You will only receive treatment if 
necessary, as outlined by our predetermined protocol.  
➢ Medications given through IV cannula site may commonly result in minor pain, 
bruising and/or infection from IV cannula site, which may require treatment with 
antibiotics.  
➢ Allergic reactions to medications are rare but possible, and allergies will be 
reviewed with you and your clinical team before proceeding with any treatment.  
➢ Known risks of blood transfusions include but are not limited to: infection or 
irritation where the needle is placed, temporary reactions such as fever, chills, or 
skin rashes. Other rare but more serious complications may occur such as allergic 
reactions, heart failure due to fluid overload, acute pulmonary edema (fluid 
leaking into the lungs), shock, or death. Transfusions of blood or blood products 
involve a small risk of transmission of diseases such as Hepatitis B (~1 in 
1,000,000), Hepatitis C (~1 in 1,200,000), and HIV/AIDS (~1 in 1,500,000). 
There is also a small risk of bacterial infection when blood products are 
transfused. 
➢ Surgical intervention (placing an external ventricular drain (EVD), decompressive 
craniectomy, or evacuation or newly formed brain bleeding) will only be taken if 
absolutely necessary, and risks and benefits of these procedures will be discussed 




There are potential benefits resulting from the study including better recovery from injury 
and faster return to baseline function, reduced length of hospital stay, reduced permanent 
disability, and improved long term functional outcomes. This study may also provide 
important clinical information that will help to clarify current guidelines for monitoring 




No compensation will be provided to participants or LARs in this study. One free parking 
voucher will be provided for each LAR throughout the duration of the study, if 
applicable. Participants will be reimbursed for any travel expenses pertaining to in person 




If you choose not to participate in this study, treatment alternatives do exist. These 
alternatives include the use of an ICP monitor and physician clinical judgment in 
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treatment, however you will not have the opportunity to be managed based on cerebral 
oxygen levels with a NIRS monitor. You may choose not to participate.  
 
Confidentiality and Privacy  
 
Any identifiable information that is obtained in connection with this study will remain 
confidential and will be disclosed only with your permission or as required by U.S. or 
state law. Examples of information that we are legally required to disclose include abuse 
of a child or elderly person, or certain reportable diseases. Information will be kept 
confidential by using only identification numbers on study forms, storing signed forms in 
locked cabinets, and password protecting data stored on a computer. When the results of 
the research are published or discussed in conferences, no information will be included 
that would reveal your identity unless your specific permission for this activity is 
obtained.  
 
We understand that information about your health is personal, and we are committed to 
protecting the privacy of that information. If you decide to be in this study, the researcher 
will get information that identifies your personal health information. This may include 
information that might directly identify you, such as his or her name and address, 
telephone number, and email address, or mobile phone number. This information will be 
de-identified at the earliest reasonable time after we receive it, meaning we will replace 
your identifying information with a code that does not directly identify you. The principal 
investigator will keep a link that identifies you and your coded information, and this link 
will be kept secure and available only to the principal investigator or selected members of 
the research team. Any information that can identify you will remain confidential. 
Information will be kept confidential by using only identification numbers on study 
forms, storing signed forms in locked cabinets, and password protecting data stored on a 
computer. The research team will only give this coded information to others to carry out 
this research study. The link to your personal information will be kept for 5 years, after 
which time the link will be destroyed and the data will become anonymous. The data will 
be kept in this anonymous form indefinitely. 
 
All health care providers subject to HIPAA (Health Insurance Portability and 
Accountability Act) are required to protect the privacy of your information. The research 
staffs at the Yale School of Medicine, Hartford Hospital and St. Francis Hospital are 
required to comply with HIPAA and to ensure the confidentiality of your information. 
 
Representatives from the Yale Human Research Protection Program, the Yale Human 
Investigation Committee (the committee that reviews, approves, and monitors research on 
human subjects) may inspect study records during internal auditing procedures. However, 
these individuals are required to keep all information confidential.  
 
Voluntary Participation and Withdrawal 
 
You are free to choose not to participate in this study. Your health care outside the study, 
the payment for your health care, and your health care benefits will not be affected if you 
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do not agree to participate. However, you will not be able to enroll in this research study 
and will not receive study procedures as a study participant if you do not allow use of 
your information as part of this study. You do not give up any of your legal rights by 
signing this form. 
 
Withdrawing from the Study 
 
If you become a subject, you are free to stop and withdraw from this study at any time 
during its course. To withdraw from the study, you or your LAR can call a member of the 
research team at any time and tell them that you no longer want to take part. This will 
cancel any future interventions or appointments.  
 
The researchers may withdraw you from participating in the research if necessary. This 
will only occur if continuation is considered unsafe or if there is a breach of 
confidentiality or blinding. If you choose not to participate or if you withdraw it will not 
harm your relationship with your own doctors or with the Yale School of Medicine, Yale 




We have used some technical terms in this form. Please feel free to ask about anything 
you don't understand and to consider this research and the permission form carefully – if 




My LAR or I have read (or someone has read to me) this form and have decided to 
participate in the project described above. Its general purposes, the particulars of my 
involvement and possible hazards and inconveniences have been explained to my 
satisfaction. My signature also indicates that I have received a copy of this consent form. 
 
You do not give up any of your legal rights by signing this form.  
 

















Signature of Person Obtaining Consent  Date 
 
 
If you have further questions about this project or if you have a research-related problem, 
you may contact the Principal Investigator, Emily J. Gilmore, MD at (***) ***-
****or the Co-Principal Investigator, Drew H. Zimmerman, PA-SII at (***) ***-****. 
If you would like to talk with someone other than the researchers to discuss problems, 
concerns, and questions, offer input, discuss situations in the event that a member of the 
research team is not available, or if you have any questions concerning your rights as a 




















































1. Al-Mufti F, Lander M, Smith B, et al. Multimodality Monitoring in Neurocritical 
Care: Decision-Making Utilizing Direct And Indirect Surrogate Markers. Journal 
of Intensive Care Medicine. 2018;34(6):449-463. 
2. Al-Rawi PG, Kirkpatrick PJ. Tissue oxygen index: thresholds for cerebral 
ischemia using near-infrared spectroscopy. Stroke. 2006;37(11):2720-2725. 
3. Alali AS, Fowler RA, Mainprize TG, et al. Intracranial pressure monitoring in 
severe traumatic brain injury: results from the American College of Surgeons 
Trauma Quality Improvement Program. Journal of neurotrauma. 
2013;30(20):1737-1746. 
4. Ayaz H, Izzetoglu M, Izzetoglu K, Onaral B. Chapter 3 - The Use of Functional 
Near-Infrared Spectroscopy in Neuroergonomics. In: Ayaz H, Dehais F, eds. 
Neuroergonomics. Academic Press; 2019:17-25. 
5. Bardt TF, Unterberg AW, Hartl R, Kiening KL, Schneider GH, Lanksch WR. 
Monitoring of brain tissue PO2 in traumatic brain injury: effect of cerebral 
hypoxia on outcome. Acta neurochirurgica Supplement. 1998;71:153-156. 
6. Bohman LE, Heuer GG, Macyszyn L, et al. Medical management of 
compromised brain oxygen in patients with severe traumatic brain injury. 
Neurocritical care. 2011;14(3):361-369. 
7. Bratton SL, Chestnut RM, Ghajar J, et al. Guidelines for the management of 
severe traumatic brain injury. VIII. Intracranial pressure thresholds. Journal of 
neurotrauma. 2007;24 Suppl 1:S55-58. 
8. Budohoski KP, Zweifel C, Kasprowicz M, et al. What comes first? The dynamics 
of cerebral oxygenation and blood flow in response to changes in arterial pressure 
and intracranial pressure after head injury. Br J Anaesth. 2012;108(1):89-99. 
9. Carney N, Totten AM, O'Reilly C, et al. Guidelines for the Management of 
Severe Traumatic Brain Injury, Fourth Edition. Neurosurgery. 2017;80(1):6-15. 
10.       Centers for Disease Control and Prevention. Report to Congress on Traumatic 
Brain Injury in the United States: Epidemiology and Rehabilitation. National 
Center for Injury Prevention and Control; Division of Unintentional Injury 
Prevention. 2015. 
11. Chesnut RM, Marshall LF, Klauber MR, et al. The role of secondary brain injury 
in determining outcome from severe head injury. The Journal of trauma. 
1993;34(2):216-222. 
12. Chesnut RM, Temkin N, Carney N, et al. A Trial of Intracranial-Pressure 
Monitoring in Traumatic Brain Injury. New England Journal of Medicine. 
2012;367(26):2471-2481. 
13. Davies DJ, Su Z, Clancy MT, et al. Near-Infrared Spectroscopy in the Monitoring 
of Adult Traumatic Brain Injury: A Review. Journal of neurotrauma. 
2015;32(13):933-941. 
14. Dewan Y, Komolafe EO, Mejia-Mantilla JH, Perel P, Roberts I, Shakur H. 
CRASH-3 - tranexamic acid for the treatment of significant traumatic brain 
injury: study protocol for an international randomized, double-blind, placebo-
controlled trial. Trials. 2012;13:87. 
 67 
15. Di Domenico SI, Rodrigo AH, Dong M, et al. Chapter 28 - Functional Near-
Infrared Spectroscopy: Proof of Concept for Its Application in Social 
Neuroscience. In: Ayaz H, Dehais F, eds. Neuroergonomics. Academic Press; 
2019:169-173. 
16. Drenckhahn C, Koch SP, Dümmler J, Kohl-Bareis M, Steinbrink J, Dreier JP. A 
validation study of the use of near-infrared spectroscopy imaging in primary and 
secondary motor areas of the human brain. Epilepsy & Behavior. 2015;49:118-
125. 
17. Farahvar A, Gerber LM, Chiu YL, Carney N, Hartl R, Ghajar J. Increased 
mortality in patients with severe traumatic brain injury treated without intracranial 
pressure monitoring. Journal of neurosurgery. 2012;117(4):729-734. 
18. Garvey AA, Kooi EMW, Smith A, Dempsey EM. Interpretation of Cerebral 
Oxygenation Changes in the Preterm Infant. Children (Basel, Switzerland). 
2018;5(7). 
19. Gerber LM, Chiu YL, Carney N, Hartl R, Ghajar J. Marked reduction in mortality 
in patients with severe traumatic brain injury. Journal of neurosurgery. 
2013;119(6):1583-1590. 
20. Ghosh A, Elwell C, Smith M. Review article: cerebral near-infrared spectroscopy 
in adults: a work in progress. Anesth Analg. 2012;115(6):1373-1383. 
21. Godoy DA, Lubillo S, Rabinstein AA. Pathophysiology and Management of 
Intracranial Hypertension and Tissular Brain Hypoxia After Severe Traumatic 
Brain Injury: An Integrative Approach. Neurosurgery Clinics of North America. 
2018;29(2):195-212. 
22. Heuer GG, Smith MJ, Elliott JP, Winn HR, LeRoux PD. Relationship between 
intracranial pressure and other clinical variables in patients with aneurysmal 
subarachnoid hemorrhage. Journal of neurosurgery. 2004;101(3):408-416. 
23. Huang SJ, Hong WC, Han YY, et al. Clinical outcome of severe head injury using 
three different ICP and CPP protocol-driven therapies. Journal of clinical 
neuroscience : official journal of the Neurosurgical Society of Australasia. 
2006;13(8):818-822. 
24. Hyttel-Sorensen S, Pellicer A, Alderliesten T, et al. Cerebral near infrared 
spectroscopy oximetry in extremely preterm infants: phase II randomised clinical 
trial. BMJ (Clinical research ed). 2015;350:g7635. 
25. Jacobsson L, Lexell J. Functioning and disability from 10 to 16 years after 
traumatic brain injury. Acta Neurologica Scandinavica. 2019;n/a(n/a). 
26. Jaeger M, Schuhmann MU, Soehle M, Nagel C, Meixensberger J. Continuous 
monitoring of cerebrovascular autoregulation after subarachnoid hemorrhage by 
brain tissue oxygen pressure reactivity and its relation to delayed cerebral 
infarction. Stroke. 2007;38(3):981-986. 
27. Kiening KL, Hartl R, Unterberg AW, Schneider GH, Bardt T, Lanksch WR. Brain 
tissue pO2-monitoring in comatose patients: implications for therapy. 
Neurological research. 1997;19(3):233-240. 
28. Kinoshita K. Traumatic brain injury: pathophysiology for neurocritical care. 
Journal of Intensive Care. 2016;4(1):29. 
29. Klein SP, Depreitere B, Meyfroidt G. How I monitor cerebral autoregulation. 
Critical care (London, England). 2019;23(1):160-160. 
 68 
30. Lassen NA, Christensen MS. PHYSIOLOGY OF CEREBRAL BLOOD FLOW. 
Br J Anaesth. 1976;48(8):719-734. 
31. Lee JK, Kibler KK, Benni PB, et al. Cerebrovascular Reactivity Measured by 
Near-Infrared Spectroscopy. Stroke. 2009;40(5):1820-1826. 
32. Maloney-Wilensky E, Gracias V, Itkin A, et al. Brain tissue oxygen and outcome 
after severe traumatic brain injury: a systematic review. Crit Care Med. 
2009;37(6):2057-2063. 
33. Marehbian J, Muehlschlegel S, Edlow BL, Hinson HE, Hwang DY. Medical 
Management of the Severe Traumatic Brain Injury Patient. Neurocritical care. 
2017;27(3):430-446. 
34. Martini RP, Deem S, Yanez ND, et al. Management guided by brain tissue 
oxygen monitoring and outcome following severe traumatic brain injury. Journal 
of neurosurgery. 2009;111(4):644-649. 
35. Mokri B. The Monro-Kellie hypothesis: applications in CSF volume depletion. 
Neurology. 2001;56(12):1746-1748. 
36. Nangunoori R, Maloney-Wilensky E, Stiefel M, et al. Brain tissue oxygen-based 
therapy and outcome after severe traumatic brain injury: a systematic literature 
review. Neurocritical care. 2012;17(1):131-138. 
37. Narotam PK, Morrison JF, Nathoo N. Brain tissue oxygen monitoring in 
traumatic brain injury and major trauma: outcome analysis of a brain tissue 
oxygen-directed therapy. Journal of neurosurgery. 2009;111(4):672-682. 
38. Oddo M, Levine JM, Mackenzie L, et al. Brain hypoxia is associated with short-
term outcome after severe traumatic brain injury independently of intracranial 
hypertension and low cerebral perfusion pressure. Neurosurgery. 
2011;69(5):1037-1045; discussion 1045. 
39. Okonkwo DO, Shutter LA, Moore C, et al. Brain Oxygen Optimization in Severe 
Traumatic Brain Injury Phase-II: A Phase II Randomized Trial. Crit Care Med. 
2017;45(11):1907-1914. 
40. Olsen A. Cognitive Control Function and Moderate-to-Severe Traumatic Brain 
Injury: Functional and Structural Brain Correlates 2014. 
41. Parmeet K, Saurabh S. Recent Advances in Pathophysiology of Traumatic Brain 
Injury. Current Neuropharmacology. 2018;16(8):1224-1238. 
42. Pascual JL, Georgoff P, Maloney-Wilensky E, et al. Reduced brain tissue oxygen 
in traumatic brain injury: are most commonly used interventions successful? The 
Journal of trauma. 2011;70(3):535-546. 
43. Prabhakar H, Sandhu K, Bhagat H, Durga P, Chawla R. Current concepts of 
optimal cerebral perfusion pressure in traumatic brain injury. J Anaesthesiol Clin 
Pharmacol. 2014;30(3):318-327. 
44. Prins M, Greco T, Alexander D, Giza CC. The pathophysiology of traumatic brain 
injury at a glance. Dis Model Mech. 2013;6(6):1307-1315. 
45. Robertson CS, Valadka AB, Hannay HJ, et al. Prevention of secondary ischemic 
insults after severe head injury. Crit Care Med. 1999;27(10):2086-2095. 
46. Roh D, Park S. Brain Multimodality Monitoring: Updated Perspectives. Curr 
Neurol Neurosci Rep. 2016;16(6):56-56. 
47. Rosner MJ, Daughton S. Cerebral perfusion pressure management in head injury. 
The Journal of trauma. 1990;30(8):933-940; discussion 940-931. 
 69 
48. Rosner MJ, Rosner SD, Johnson AH. Cerebral perfusion pressure: Management 
protocol and clinical results. Journal of neurosurgery. 1995;83(6):949-962. 
49. Saatman KE, Duhaime A-C, Bullock R, et al. Classification of traumatic brain 
injury for targeted therapies. Journal of neurotrauma. 2008;25(7):719-738. 
50. Steiner LA, Pfister D, Strebel SP, Radolovich D, Smielewski P, Czosnyka M. 
Near-infrared spectroscopy can monitor dynamic cerebral autoregulation in 
adults. Neurocritical care. 2009;10(1):122-128. 
51. Sternbach GL. The Glasgow coma scale. The Journal of emergency medicine. 
2000;19(1):67-71. 
52. Stewart C, Haitsma I, Zador Z, et al. The new Licox combined brain tissue 
oxygen and brain temperature monitor: assessment of in vitro accuracy and 
clinical experience in severe traumatic brain injury. Neurosurgery. 
2008;63(6):1159-1164; discussion 1164-1155. 
53. Steyerberg EW, Mushkudiani N, Perel P, et al. Predicting outcome after traumatic 
brain injury: development and international validation of prognostic scores based 
on admission characteristics. PLoS medicine. 2008;5(8):e165; discussion e165. 
54. Stiefel MF, Spiotta A, Gracias VH, et al. Reduced mortality rate in patients with 
severe traumatic brain injury treated with brain tissue oxygen monitoring. Journal 
of neurosurgery. 2005;103(5):805-811. 
55. Stiefel MF, Udoetuk JD, Spiotta AM, et al. Conventional neurocritical care and 
cerebral oxygenation after traumatic brain injury. Journal of neurosurgery. 
2006;105(4):568-575. 
56. Suzuki S, Takasaki S, Ozaki T, Kobayashi Y. Tissue oxygenation monitor using 
NIR spatially resolved spectroscopy. Paper presented at: Proceedings of the 1999 
Optical Tomography and Spectroscopy of Tissue III1999; Bellingham, WA, 
United States 
              San Jose, CA, USA. 
57. Talving P, Karamanos E, Teixeira PG, et al. Intracranial pressure monitoring in 
severe head injury: compliance with Brain Trauma Foundation guidelines and 
effect on outcomes: a prospective study. Journal of neurosurgery. 
2013;119(5):1248-1254. 
58. Tasneem N, Samaniego EA, Pieper C, et al. Brain Multimodality Monitoring: A 
New Tool in Neurocritical Care of Comatose Patients. Critical care research and 
practice. 2017;2017:6097265. 
59. Thurman DJ, Alverson C, Dunn KA, Guerrero J, Sniezek JE. Traumatic brain 
injury in the United States: A public health perspective. The Journal of head 
trauma rehabilitation. 1999;14(6):602-615. 
60. van den Brink WA, van Santbrink H, Steyerberg EW, et al. Brain oxygen tension 
in severe head injury. Neurosurgery. 2000;46(4):868-876; discussion 876-868. 
61. Weir J, Steyerberg EW, Butcher I, et al. Does the extended Glasgow Outcome 
Scale add value to the conventional Glasgow Outcome Scale? Journal of 
neurotrauma. 2012;29(1):53-58. 
62. Werner C, Engelhard K. Pathophysiology of traumatic brain injury. Br J Anaesth. 
2007;99(1):4-9. 
63. Whiteneck GG, Cuthbert JP, Corrigan JD, Bogner JA. Prevalence of Self-
Reported Lifetime History of Traumatic Brain Injury and Associated Disability: A 
 70 
Statewide Population-Based Survey. The Journal of head trauma rehabilitation. 
2016;31(1):E55-62. 
64. Zoerle T, Lombardo A, Colombo A, et al. Intracranial pressure after subarachnoid 
hemorrhage. Crit Care Med. 2015;43(1):168-176. 
65. Zweifel C, Castellani G, Czosnyka M, et al. Noninvasive Monitoring of 
Cerebrovascular Reactivity with Near Infrared Spectroscopy in Head-Injured 
Patients. Journal of neurotrauma. 2010;27(11):1951-1958. 
 
 
